#### Check for updates

#### **OPEN ACCESS**

EDITED BY Junmin Zhang, Lanzhou University, China

#### REVIEWED BY

Jue Wang, Macau University of Science and Technology, Macao SAR, China Songxiao Xu, University of Chinese Academy of Sciences, China

\*CORRESPONDENCE Yijun Wang, ⊠ efywyj@163.com Yanhong Pan, ⊠ happypan123@126.com

RECEIVED 14 March 2023 ACCEPTED 24 July 2023 PUBLISHED 02 August 2023

#### CITATION

Pan Y, Wan P, Zhang L, Wang C and Wang Y (2023), Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis. *Front. Pharmacol.* 14:1185987. doi: 10.3389/fphar.2023.1185987

#### COPYRIGHT

© 2023 Pan, Wan, Zhang, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis

Yanhong Pan<sup>1,2</sup>\*, Panting Wan<sup>1</sup>, Li Zhang<sup>1</sup>, Cuirong Wang<sup>1</sup> and Yijun Wang<sup>1</sup>\*

<sup>1</sup>Department of Pharmacy, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China, <sup>2</sup>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China

**Introduction:** Elemene injection and oral emulsion, known as elemene, have been utilized have been used in adjuvant therapy for cancer patients in China for more than 20 years. In order to evaluate the efficacy and potential risks of the treatments in cancer patients undergoing chemotherapy, a system review and meta-analysis were conducted. Additionally, the factors that may influence the outcomes were also explored.

**Methods:** A comprehensive search was conducted across various databases including PubMed, Cochrane Library, Web of Science, EMBASE, CKNI, Wan Fang, and VIP databases. Meta-regression, subgroup, and sensitivity analyses were conducted to explore the heterogeneity. GRADE system and TSA were used to assess the strength of evidence and robustness of the results.

**Results:** The pooled data showed that combination with elemene could improve the response rate (RR:1.48, 95%Cl:1.38–1.60, p < 0.00001), disease control rate (RR:1.20, 95%Cl:1.15–1.25, p < 0.00001), the rate of quality-of-life improvement and stability (WMD:1.31, 95% Cl:1.12–1.53, p = 0.0006), immune function (CD4<sup>+</sup>/ CD8<sup>+</sup>: WMD:0.33, 95% Cl:0.24–0.42, p < 0.00001), survival rate (1-year, RR:1.34, 95% Cl:1.15–1.56, p = 0.0002; 2-year, RR:1.57, 95% Cl:1.14–2.16, p = 0.006), and decrease the prevalence of most chemotherapy-induced side effects, especially leukopenia (III-IV) (RR:0.46, 95% Cl:0.35–0.61, p < 0.00001), thrombocytopenia (RR:0.86, 95% Cl:0.78–0.95, p = 0.003), and hemoglobin reduction (RR:0.83, 95% Cl:0.73–0.95, p = 0.007). However, the administration of elemene has been found to significantly increase the incidence of phlebitis in patients undergoing chemotherapy (RR:3.41, 95% Cl:1.47–7.93, p = 0.004). Meta-regression and subgroup analyses discovered that the outcomes were rarely influenced by CR, CT, and dosage of elemene (DE) but the cycle number of elemene (CNE) and TT were the main sources of heterogeneity.

**Discussion:** As the treatment time and the number of cycles increased, the efficacy of the elemene combination decreased across various aspects. Thus, shorter duration and fewer cycles are recommended.

#### KEYWORDS

elemene, chemotherapy, cancer patients, efficacy, side effects, variables

# Introduction

Cancer is a serious health problem threatening human life all over the world. According to the survey, more than 1.6 million people are diagnosed with cancer and 1.2 million people died of it every year in China (Fan et al., 2014). Even in developed countries, such as the United States, more than 1.8 million new cancer cases and 0.6 million cancer deaths occurred in 2021 (Siegel et al., 2021). Chemotherapy is one of the main treatments for cancer since 1940, which can effectively kill cancer cells. However, no selective killing effect of these drugs caused inevitable body damage during the treatments. Patients frequently experience hair loss, digestive tract reactions, myelosuppression, liver and kidney dysfunction, and other adverse effects. Some patients even die of severe toxic reactions induced by chemotherapy drugs (Diasio and Offer, 2022). Multidrug resistance (MDR) is another problem that limited its application in clinics. Metabolism of xenobiotics, efflux of drugs, growth factors, stress-associated cellular states, and plasticity of cancer cells are involved in MDR (Bukowski et al., 2020; Jewer et al., 2020; Zhang K. et al., 2022). Therefore, the development of new treatments to overcome these disadvantages is quite necessary.

In recent years, active ingredients derived from natural plants have attracted the attention of researchers and developed due to their anticancer activity and the richness of candidate resources. βelemene, the predominant non-cytotoxic anticancer component of Curcuma wenyujin Y.H.Chen & C.Ling and Curcuma zedoaria (Christm.) Roscoe (Tao et al., 2016), has been reported to inhibit the proliferation, metastasis, and metabolism of cancer cells, induce apoptosis, and regulate immunity (Pan et al., 2019; Cheng et al., 2022; Kong et al., 2022). It can improve the sensitivity of cancer cells radiotherapy and chemotherapeutic drugs to without myelosuppression and hepatorenal toxicity (Liu et al., 2015; Mu et al., 2016; Zhou et al., 2016; Liu et al., 2020). Elemene oral emulsion (85%  $\beta$ -elemene) and elemene injection (85%  $\beta$ -elemene) collectively referred to as elemene in this study were approved by the China Food and Drug Administration (CFDA) for the therapy of various cancer (Bai et al., 2021). Especially elemene injection has been used in clinical adjuvant therapy for more than 20 years in China. Numerous studies have reported that the incorporation of elemene injection or oral emulsion alongside chemoradiotherapy can mitigate side effects and improve the overall quality of life (Chang et al., 2017; Wang et al., 2019). However, conclusions diverge when it comes to disease control rate (DCR), response rate, and survival rate (Zeng et al., 2011; Zheng et al., 2014; Lei et al., 2018). This discrepancy can be attributed to various factors, including the specific cancer type, sample size (SZ), chemotherapy regimens (CR), treatment time (TT), cycle number of elemene (CNE), and dosage of elemene (DE). Furthermore, few studies have comprehensively evaluated the advantages and potential risks associated with the combined use of elemene and chemotherapy. Therefore, the purpose of this study was to assess the clinical benefit and potential hazards associated with the administration of elemene to cancer patients undergoing chemotherapy in terms of response rate, DCR, side effects, quality of life, survival rate, and immune function, and to look for possible causes.

# Methods

# Protocol and registration

This research was guided by the Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 (Shamseer et al., 2015) and registered at PROSPERO (http://www. crd.york.ac.uk/PROSPERO). The registration number is CRD42022330190.

# Search strategy

Electronic literature in Chinese and English that related to elemene, chemotherapy, and their items were searched in PubMed, Cochrane Library, Web of Science, EMBASE, CKNI, Wan Fang, and VIP databases from inception to April 2022. The literature search was finished by the two independent reviewers C.R.W. and L.Z. The search concepts were shown as follows:

For the English databases: 1. Elemene OR ELE OR Elemene Emulsion OR Elemene Injection AND 2. Chemotherapy OR Chemical therapy. For the Chinese databases: 1. Lanxiangxi (Elemene/ ELE) OR Lanxiangxi zhusheye (Elemene Injection) OR Lanxiangxi ru (Elemene Emulsion) AND 2. Hualiao (Chemotherapy/Chemical therapy), and their related terms as MeSH terms, title, and abstract.

### Inclusion and exclusion criteria

Inclusion criteria: 1) Patients were diagnosed with cancer by pathology, cytology, or imaging; 2) Clinical trials; 3) Studies comparing the combination of elemene and chemotherapy with the same chemotherapy; 4) Studies have reported more than one of the following primary or secondary outcomes.

Exclusion criteria: 1) Studies lacking information on cancer patient diagnostics; 2) Nonclinical studies including observational studies, systematic reviews, letters, editorials, clinical guidelines, and commentaries; 3) Studies lacking chemotherapy-only group or combination group; 4) Studies failing to report at least one of the following primary or secondary outcomes.

# Data extraction

Data extraction was carried out by two researchers Y.H.P. and P.T.W. First, the quality of journals was evaluated and the references were screening the title and abstract to remove duplicate and unrelated studies. Then, the studies in accordance with the inclusion criteria were identified by reading the full text. When disagreements arise, the third reviewer Y.J.W. was discussed to reach a consensus. Extracted data included the basic characteristics, such as cancer type, sample size, treatment time, intervention, and outcomes.

# Primary outcome

Response rate, adverse effects, Karnofsky Performance Status (KPS), quality of life improvement and stability rate, and immunocyte.

#### Secondary outcome

DCR, survival rate, and lung cancer symptom scale observer scale (LCSS).

#### Risk of bias and quality assessment

Cochrane risk assessment tool was used to assess the risk of bias in the included studies by two independent researchers Y.H.P. and P.T.W., and any conflicts were resolved through negotiation. Review Manager 5.3 software was used to record the seven domains: random sequence generation (selection bias), allocation concealment (selection bias), masking of participants and personnel (performance bias), masking of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias. Included studies were classified as "low," "high," and "unclear" risk of bias, colored green, yellow, and red and presented as "+," "–," and "?." GRADEproflier 3.2.2 software was utilized to evaluate the quality of evidence, and outcomes were rated as "high," "moderate," "low," and "very low" (Guyatt et al., 2011).

#### Data synthesis and statistical analysis

Review Manager 5.3 and Stata/MP 14.0 software were used. Continuous outcomes were analyzed using Weighted mean difference (WMD) and 95% confidence interval (CI) and dichotomous outcomes as risk ratios (RR) and 95% CI. *p*-value and I<sup>2</sup> statistics were used to check the heterogeneity of studies. If I<sup>2</sup> <50% or p > 0.1, a fixed-effects model was applied (Higgins and Thompson, 2002). Otherwise, a random-effects model was used. Publication bias for the same outcome which included more than 10 studies was evaluated by Funnel plots. A sensitivity analysis was performed to evaluate the stability of the results by eliminating the studies one by one (Liu et al., 2022). Meta-regression and subgroup analysis were utilized to evaluate what caused the heterogeneity (Zhu et al., 2022).

#### Trial sequential analysis

The TSA software (version 0.9.5.10 Beta) was utilized to evaluate the robustness of the findings in cases where the number of included studies exceeded four. The required information size (RIS) was calculated according to a type I error value of 5%, a power of 80, and a relative risk reduction based on studies with low bias. The reliability of the result was established if the cumulative sample size reached the RIS or the cumulative Z curve intersected the monitoring boundary (Zhang L. et al., 2022).

# Results

#### Study selection and characteristic information

As shown in Figure 1, we achieved 2, 7, 5, 4, 72, 81, and 30 records from Pubmed, Cochrane Library, EMBASE, Web of

Science, CNKI, WANFANG, and VIP databases, respectively. 110 studies were identified after removing duplication. After evaluating the journal's quality and reading the title and abstract, 55 publications were removed. 17 records were further excluded for the reason of lack of a control group or combination group, a combination of chemotherapy with other interventions, and insufficient data. 38 clinical studies, including 2709 patients, 12 types of cancer, and 35 chemotherapy regimens were finally chosen for this study (Zhang, 1997; Qin et al., 1998; Zhao et al., 1999; Zheng et al., 1999; Liu, 2000; Chen et al., 2005; Chen et al., 2008; Gu et al., 2009; Zhou et al., 2009; Zhou, 2010; Fan et al., 2011; Lu and Zhao, 2011; Zeng et al., 2011; Chen et al., 2012; Wang et al., 2012; Zhao et al., 2012; Zhang et al., 2013a; Feng and Zhao, 2013; Huang et al., 2013; Song et al., 2015; Xu et al., 2017; Lei et al., 2018; Wang et al., 2018; Wu et al., 2018; Xu et al., 2018; Zhao et al., 2018; Shi et al., 2019; Zhang et al., 2019; Zhong and Hao, 2019; Qian et al., 2020; Yu et al., 2020; Fan and Wang, 2021; Han et al., 2021; Liu et al., 2021; Tao et al., 2021). In these studies, elemene, no matter whether administered orally or by injection, was a prescription drug approved for marketing in China. The detailed characteristics and information are summarized in Table 1.

#### Risk of bias assessment

The risk of bias was assessed and presented in Figure 2 and Figure 3. 78.9% of the studies were randomly designed and 31.6% had low risks of allocation concealment. For attrition bias, all trials were ranked as low risk. However, the majority of the studies did not mention whether the process was double-blind. For reporting bias, all of the studies were ranked as low risk, and for most of them, the presence of other biases was not clearly indicated.

# Elemene improved the response rate and disease control rate of cancer patients treated with chemotherapy

35 studies reported changes in response rate while 30 pieces of research revealed variations of DCR after therapy. The studies involving response rate and DCR were homogenous ( $I^2 = 0\%$ , p = 0.89; I<sup>2</sup> = 9%, p = 0.33 Figures 4A,B), so fixed-effects models were selected for their analysis. The pooled data showed that combining with elemene had a better response rate and DCR than chemotherapy alone (RR:1.48, 95%CI:1.38-1.60, *p* < 0.00001; RR:1.20, 95%CI:1.15–1.25, *p* < 0.00001, Figures 4A,B). The meta-regression analysis showed CNE could moderate the response rate and DCR (p = 0.082 and p = 0.019, Supplementary Table S1), while SZ, CR, CT, TT, DE, and DDE did not have a significant impact. Subgroup analysis discovered that the improvement of elemene on response rate and DCR might disappear when its cycle number was more than 6 (Supplementary Figures S1A, B). According to the funnel plots for the included studies, we believed that the publication bias was extremely low (Supplementary Figures S3A, B). The sensitivity analysis demonstrated that the combined estimates remained unaffected by any individual study (Supplementary Figures S2A, B). The TSA analysis showed the sample size reached RIS, with the Z



curve crossing the conventional and TSA boundaries (Supplementary Figures S6A, B), indicating the robustness of these findings.

# The influence of elemene on the side effects of chemotherapy

35 publications with 2397 patients studied the influence of elemene on the adverse reactions of chemotherapy, including leukopenia, thrombocytopenia, and digestive tract reactions (Table 1; Figure 5; Supplementary Figures S4, S5).

There was no heterogeneity in studies involving leukopenia (III-IV), thrombocytopenia, and liver function damage (I<sup>2</sup> = 0, p = 0.94; I<sup>2</sup> = 0%, p = 0.44; I<sup>2</sup> = 21%, p = 0.24). The overall results showed that elemene reduced the incidence of chemotherapy-induced leukopenia (III-IV), thrombocytopenia, and liver function damage in cancer patients (RR:0.46, 95% CI: 0.35–0.61, p < 0.00001; RR:0.86, 95% CI:0.78–0.95, p = 0.003; RR: 0.82, 95% CI:0.68–1.00, p = 0.04, Figures 5A–C). A random-effects

model was applied because of the heterogeneity ( $I^2 = 43\%$ , p = 0.03, Figure 5D), and an improvement of digestive tract reactions was seen in cancer patients who received elemene in combination with chemotherapy (RR:0.81, 95% CI:0.70-0.94, p = 0.006, Figure 5D). However, evidence of publication bias was observed through the presence of asymmetry in the funnel plots shown in Supplementary Figures S3C-F. Meta-regression analysis only discovered a significant association between TT with the prevalence of digestive tract reactions (p = 0.043, Supplementary Table S1). Subgroup analysis showed that the prevalence of digestive tract reactions was remarkably reduced by elemene when TT was no more than 42 days (RR:0.70, 95% CI:0.55–0.91, *p* = 0.007, Supplementary Figure S4B), while a slight reduction of the incidence of liver function damage occurred when the CNE value ranged from 2-3 (RR:0.76, 95% CI:0.55–1.03, *p* = 0.08, Supplementary Figure S4A). Sensitivity analysis showed the results were stable (Supplementary Figures S2C–F).

Hemoglobin reduction, neurotoxicity, myelosuppression, anemia, and kidney function damage are also common during chemotherapy. In this research, we found the included clinical

Study	Cancer	Sample size	Treatment	Interver	ntion	Outcomes	Dosage	Cycle	Drug
	type	Experimental/ Control	time	Experimental	Control		of elemene	number of elemene	delivery of elemene
Qin et al. (1998)	Lung cancer	27/29	>56 days, <63 days	Elemene + CTV	CTV	1, 2, 3, 4	400 mg/Day	2	Injection
Xu et al. (2018)	Lung cancer	50/50	63 days	Elemene + GP	GP	1, 2, 3, 6, 8	400 mg/Day	3	Injection
Zhou et al. (2009)	Lung cancer	44/40	>63 days	Elemene + Paclitaxel	Paclitaxel	1, 2, 3	400 mg/ m²/Day	4	Injection
Zhang (1997)	Lung cancer	16/17	28 days	Elemene + Cisplatin + VP-16	Cisplatin + VP-16	1	400 mg/ m²/Day	2	Injection
Song et al. (2015)	Lung cancer	60/60	>63 days	Elemene + NP	NP	1, 3, 5	400 mg/Day	4	Injection
Lei et al. (2018)	Lung cancer	29/29	>42 days	Elemene + TP/ GP/PC	TP/GP/PC	1, 2, 4, 7	500 mg/Day	>6	Injection
Zhao et al. (2018)	Lung cancer	35/35	>63 days	Elemene + TP	TP	1, 2, 3, 6, 7	600 mg/Day	4	Injection
Chen et al. (2008)	Lung cancer	68/71	42 days	Elemene + DC	DC	1, 2, 3, 5, 6	400 mg/Day	2-3	Injection
Liu (2000)	Lung cancer	23/20	56–84 days	Elemene + MVP	MVP	1, 3, 6	500 mg/Day	2	Injection
Wang et al (2012)	Lung cancer	31/30	28 days	Elemene + TC	TC	1, 2, 3, 5	500 mg/Day	2	Injection
Zhou (2010)	Lung cancer	36/21	>63 days	Elemene + TP	TP	1, 2, 3, 7	400 mg/ m²/Day	ND	Injection
Fan and Wang (2021)	Lung cancer	36/36	63 days	Elemene + Pemetrexed + Cisplatin + Gefitinib	Pemetrexed + Cisplatin + Gefitinib	1, 2, 5, 6, 7, 8	400 mg/Day	3	Injection
Chen et al. (2005)	Lung cancer	33/30	56 days	Elemene + Docetaxel	Docetaxel	1, 2, 3, 6	800 mg/Day	2	Injection
Zhang et al. (2019)	Lung cancer	40/33	42 days	Elemene + GP	GP	1, 2, 3, 6	400 mg/Day	3	Injection
Fan et al. (2011)	Gastric cancer	41/40	42 days	Elemene + XELOX	XELOX	1, 2, 3, 7	100 mg/Day	2	Injection
Zeng et al. (2011)	Gastric cancer	25/24	56 days	Elemene + FOLFOX4	FOLFOX4	1, 2, 3, 5, 6	500 mg/Day	4	Injection
Qian et al. (2020)	Gastric cancer	35/36	>42 days	Elemene + SOX	SOX	1, 3, 6	400 mg/Day	2	Injection
Tao et al. (2021)	Gastric cancer	38/38	42 days	Elemene + SOX	SOX	1, 2, 3	176 mg × 3/Day	2	Orally
Yu et al. (2020)	Gastric cancer	45/45	42 days	Elemene + FOLFOX4	FOLFOX4	1, 2, 3	500 mg/Day	3	Injection
Zhong and Hao (2019)	Gastric cancer	30/30	42 days	Elemene + XELOX + Trastuzumab	XELOX + Trastuzumab	1, 2, 7	500 mg/Day	2	Injection

#### TABLE 1 The characteristics of included studies.

(Continued on following page)

delivery of elemene

Injection

number of elemene

6

# Experimental/ Control of elemene Wang Gastric 30/30 >63 days Elemene + XELOX 1, 2, 4, 6 600 mg/Day XELOX et al. cancer

#### TABLE 1 (Continued) The characteristics of included studies.

(2018)									
Bi et al. (2012)	Gastric cancer	25/24	56 days	Elemene + FOLFOX4	FOLFOX4	1, 2, 3, 5, 6	500 mg/Day	4	Injection
Chen et al. (2022)	Gastric cancer	17/22	63 days	Elemene + Lobaplatin + Capecitabine + Oxaliplatin	Lobaplatin + Capecitabine + Oxaliplatin	3, 6	600 mg/Day	2	Injection
Han et al. (2021)	Breast cancer	56/49	>63 days	Elemene + TAC	TAC	1, 2, 3, 6, 7	400–600 mg/ Day	6	Injection
Xu et al. (2017)	Breast Cancer	42/42	>63 days	Elemene + TAC	TAC	1, 3, 7	400–600 mg/ Day	6	Injection
Zhao et al. (2012)	Liver cancer	21/20	56 days	Elemene + Cisplatin + 5-Fu + Epirubicin + Mitomycin + Lipiodol	Cisplatin + 5-Fu + Epirubicin + Mitomycin + Lipiodol	1, 2, 3, 5	200 mg/Day	2	Injection
Lu and Zhao (2011)	Liver cancer	31/30	>56 days, <63 days	Elemene + 5-Fu/ FUDR + Oxaliplatin + Lipiodol	5-Fu/FUDR + Oxaliplatin + Lipiodol	1, 2, 3, 4, 7	800 mg/Day	2	Injection
Zhao et al. (1999)	Acute myelocytic leukemia	18/12	14 days	Elemene + Ara-C + VP-16	Ara-C + VP-16	1	800 mg/Day	2	Injection
Zheng et al. (1999)	Acute myelocytic leukemia	20/23	12–15 days	Elemene + HA	HA	1, 3	800 mg/Day	2	Injection
Zheng et al. (2014)	Acute myelocytic leukemia	120/121	36–42 days	Elemene + HAA	HAA	1, 3	800 mg/Day	2	Injection
Gu et al. (2009)	Lung cancer, Esophagus cancer, Gastric cancer, Colorectal cancer, Non- Hodgkin's lymphoma	70/60	42 days	Lung cancer, Elemene + EP/ NP; Esophagus cancer, Elemene + CF/DF; Gastric cancer, Elemene + CF/DF/ECF; Colorectal cancer, Elemene + Oxaliplatin + CF/ 5-Fu; Non- Hodgkin's lymphoma, Elemene + CHOP	Lung cancer, EP/NP; Esophagus cancer, CF/ DF; Gastric cancer, CF/ DF/ECF; Colorectal cancer, Oxaliplatin + CF/5-Fu; Non- Hodgkin's lymphoma, CHOP	1, 2, 3	800 mg/Day	2	Injection
Huang et al. (2013)	Gastric cancer, Colorectal cancer, Liver cancer, Breast cancer, Pancreatic cancer, Ovarian cancer	28/34	14 days	Gastric cancer, Elemene + DCF; Colorectal cancer, Elemene + OLF/ FOLFOX4; Liver cancer, Elemene + Sorafenib; Breast cancer, Elemene + CMF; Pancreatic cancer, Elemene + GP; Ovarian cancer, Elemene + TC	Gastric cancer, DCF; Colorectal cancer, OLF/ FOLFOX4; Liver cancer, Sorafenib; Breast cancer, CMF; Pancreatic cancer, GP; Ovarian cancer, TC	1, 3, 5	800 mg/Day	2	Injection

(Continued on following page)

Study	Cancer	Sample size	Treatment	Interver	ntion	Outcomes	Dosage	Cycle	Drug
	type	Control	ume	Experimental	Control		elemene	of elemene	of elemene
Zhang et al. (2013a)	Multiple Myeloma	13/12	>63 days	Elemene + VAD	VAD	1, 2, 3, 5, 7	400 mg/Day	4	Injection
Feng and Zhao (2013)	Non- Hodgkin lymphoma	38/34	>63 days	Elemene + CHOPE	CHOPE	1, 2, 3	300 mg/Day	ND	Injection
Shi et al. (2019)	Esophageal cancer	21/22	42 days	Elemene + Docetaxel + Oxaliplatin	Docetaxel + Oxaliplatin	1, 2, 3, 4, 5, 7	800 mg/Day	2	Orally
Chen et al. (2012)	Esophageal cancer	18/18	>63 days	Elemene + Paclitaxel	Paclitaxel	1, 2, 3, 5	800 mg/Day	2	Injection
Wu et al. (2018)	Malignant pleural mesothelioma	31/31	≥42 days	Elemene + PC	РС	1, 2, 3, 6	200 mg/ m²/Day	ND	Injection
Liu et al. (2021)	Colorectal cancer	35/35	>63 days	Elemene + XELOX	XELOX	3, 7	400 mg/Day	6–8	Injection

#### TABLE 1 (Continued) The characteristics of included studies.

Outcomes: 1, Response rate, 2, DCR, 3, Adverse effects, 4; KPS, 5, Quality of life improvement and stability rate, 6, Survival rate, 7, Immunocyte, 8, LCSS; TAC, Docetaxel + Cyclophosphamide + Doxorubicin; CTV, Cyclophosphamide + Adriamycin pyranodoxorubicin + Vncristine; GP, Gemcitabine + Cisplatin; CHOPE, Cyclophosphamide + Idarubicin + Vindesine + Dexamethasone + VP-16; XELOX, Oxaliplatin + Capecitabine; NP, Vinorelbine + Cisplatin; VAD, Vincristine + Adriamycin + Dexamethasone; DCF, Docetaxel + Cisplatin + 5-Fu; CMF, Cyclophosphamide + Methotrexate + 5-Fu; TC, Paclitaxel + Carboplatin; FOLFOX6, Oxaliplatin 80–100 mg/m<sup>2</sup> + Calcium folinate 200 mg/m<sup>2</sup>; FO, Pemetrexed + Cisplatin; TP, Paclitaxel + Cisplatin; DC, Cisplatin + Docetaxel; HA, Harringtonine + Cytarabine; MVP, Mitomycin + Vindesine + Cisplatin; EP, VP-16 + Cisplatin; CF, Carboplatin + 5-Fu; DF, Cisplatin + 5-Fu; ECF, Epirubicin + Cisplatin + 5-Fu; CHOP, Cyclophosphamide + Doxorubicin + Vincristine + Prednisone; OLF, Oxaliplatin 130 mg/m<sup>2</sup> + Calcium folinate 200 mg/m<sup>2</sup> + 5-Fu 400 mg/m<sup>2</sup>; FOLFOX4, Oxaliplatin 85 mg/m<sup>2</sup> + Calcium folinate 200 mg/m<sup>2</sup> + 5-Fu 400 mg/m<sup>2</sup>; SOX, Oxaliplatin + Tegafur; HAA, Harringtonine + Aclacinomycin + Cytarabine;



studies on hemoglobin reduction, neurotoxicity, and anemia were homogeneous (I<sup>2</sup> = 9%, p = 0.36; I<sup>2</sup> = 0%, p = 0.84, I<sup>2</sup> = 24%, p = 0.26, Figures 5E,F,H), while the ones on myelosuppression and kidney function damage were heterogeneous (I<sup>2</sup> = 87%, p < 0.00001, Figure 5G; I<sup>2</sup> = 73%, p = 0.01; Supplementary Figure S5). The summarized results discovered that the inclusion of elemene was less likely to cause hemoglobin reduction and anemia than chemotherapy alone (RR:0.83, 95% CI:0.73–0.95, p = 0.007, Figure 5E; RR:0.84, 95% CI:0.70–1.00, p = 0.05; Figure 5H). However, no significant difference was observed in terms of

neurotoxicity, myelosuppression and kidney function damage (RR:0.81, 95% CI:0.61–1.07, p = 0.14, Figure 5F; RR:0.75, 95% CI:0.53–1.05, p = 0.09; Figure 5G; RR:0.59, 95% CI:0.26–1.37, p = 0.22; Supplementary Figure S5). These factors were confirmed to be stable through sensitivity analysis (Supplementary Figures S2G–K). Meta-regression analysis also discovered no significant association between hemoglobin reduction, neurotoxicity, anemia, and kidney function damage with variables shown in Supplementary Table S1 (p > 0.1), but CNE was the source of heterogeneity of myelosuppression (p = 0.018). Subgroup analysis confirmed the



combination group exhibited a significantly reduced incidence of myelosuppression and kidney function damage when elemene was administered for only three cycles (RR:0.61, 95% CI:0.45–0.81, p =0.0008, Supplementary Figure S4C; RR:0.42, 95% CI:0.22-0.80, p = 0.009; Supplementary Figure S4E), while slightly decreased the occurrence of anemia in patients with gastric cancer (RR:0.53, 95% CI:0.28-1.03, p = 0.06, Supplementary Figure S4D). Longterm use of chemotherapy drugs can easily lead to phlebitis, which is also the main adverse reaction of elemene injection, with an incidence of about 10% (Zhai et al., 2018). Unsurprisingly, the pooled results showed that elemene aggravated the incidence of phlebitis in patients undergoing chemotherapy (RR:3.41, 95% CI: 1.47–7.93, p = 0.004, Figure 5I). Sensitivity analysis found that Chen et al. 2008 influenced this result (Supplementary Figure S3L), which might be related to the use of dexamethasone before chemotherapy in this study.

For leukopenia (III-IV), its Z curve met the RIS and TSA boundary implying the benefit of the combination was conclusive (Supplementary Figure S6C). Although the cumulative Z curves for thrombocytopenia, digestive tract reactions, hemoglobin reduction, and myelosuppression did not reach the RIS, the crossing conventional boundary and TSA boundary suggested that their pooled results were not randomized (Supplementary Figures S6D, F, G, I). However, TSA for liver function damage, neurotoxicity, and anemia showed the cumulative Z value missed the RIS (6218, 4897, 3914, respectively) and TSA boundary, which suggested the conclusion needed to be confirmed by subsequent studies (Supplementary Figures S6E, H, J).

Based on the above results, we believed that elemene could reduce the occurrence of most chemotherapy-induced side effects, especially leukopenia, thrombocytopenia, and digestive tract reactions. However, the cycle number of elemene must be controlled.

# The efficacy of elemene combined with chemotherapy on the percentage of immunocytes

Studies about CD3<sup>+</sup> T cells, CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, and CD4<sup>+</sup>/CD8<sup>+</sup> ratio were statistically heterogeneous (I<sup>2</sup> = 85%, p < 0.00001; I<sup>2</sup> = 93%, p < 0.00001; I<sup>2</sup> = 85%, p < 0.00001; I<sup>2</sup> = 59%, p = 0.02, Figure 6). Combining with elemene increased the percentage of

CD3<sup>+</sup> T cells, CD4<sup>+</sup> T cells and CD4<sup>+</sup>/CD8<sup>+</sup> ratio of chemotherapy patients (WMD:6.48, 95% CI:4.40-8.57, p < 0.00001, Figure 6A; WMD:6.62, 95% CI:4.99-8.24, *p* < 0.00001; Figure 6C; WMD:0.33, 95% CI:0.24-0.42, p < 0.00001; Figure 6D). However, it had no impact on the proportion of CD8<sup>+</sup> T cells (WMD: 0.49, 95% CI: 2.59–1.60, p = 0.64, Figure 6B). The funnel plot also suggested a publication bias for studies about CD4+ T cells (Supplementary Figure S3G). Sensitivity and meta-regression analysis did not identify any studies or variables that could influence the results (Supplementary Figures S3M–P, *p* > 0.1; Supplementary Table S1). Subgroup analysis showed that the presence of CNE CT, DE, and TT contributed to the heterogeneity observed in the studies regarding the proportion of CD3<sup>+</sup> T cells, CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, and the CD4<sup>+</sup> T cells to CD8<sup>+</sup> T cells ratio, respectively (Supplementary Figures S4F-I). Elemene could not significantly enhance the percentage of CD3+ T cells in chemotherapy patients after cycles (WMD:4.37, 95% CI: 3.96-12.70, 6 D 0.30 Supplementary Figure S4F). However, it did increase the percentage of CD8+ T cells in liver cancer patients, while decreasing their percentage in colorectal cancer patients (WMD: 5.84, 95% CI:4.55–7.13, p < 0.00001; WMD: 4.09, 95% CI: 7.95 to -0.23, p = 0.04, Supplementary Figure S4G). Furthermore, subgroup analysis demonstrated that elemene remarkably elevated the CD4+ T cells to CD8+ T cells ratio in chemotherapy patients when the treatment time exceeded 42 days (WMD:0.36, 95% CI:0.27–0.45, *p* < 0.00001, Supplementary Figure S4I), suggesting that elemene had the potential to improve the immune function of chemotherapy patients. The cumulative Z curves obtained from TSA indicated that the results were robust, as they reached the RIS or TSA boundaries, except for CD8<sup>+</sup> T cells which lost the RIS, conventional boundary, and TSA boundary (Supplementary Figures S6K-N). However, it is important to note that the result regarding CD8<sup>+</sup> T cells may change in the future with a larger sample size.

#### The impact of elemene on the quality of life among cancer patients undergoing chemotherapy

The rate of improvement and stability in quality of life and KPS are commonly used to evaluate the quality of life of cancer patients

	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fix	ed, 95% Cl
	Bi et al. 2012	15	25	10	24	2.0%	1.44 [0.81, 2.55]	_	
	Chen et al. 2005	14	33	11	30	2.3%	1.16 [0.63, 2.14]		· · ·
	Chen et al. 2012	4	18	3	18	0.6%	1.33 [0.35, 5.13]		· · · · ·
	Chen et al. 2008	30	68	19	71	3.6%	1.65 [1.03, 2.63]		
	Fan et al. 2011	24	41	19	40	3.8%	1.23 [0.81, 1.87]	-	
	Fan and Wang 2021	28	36	19	36	3.7%	1.47 [1.03, 2.10]		
	Feng and Zhao 2013	31	38	14	34	2.9%	1.98 [1.29, 3.04]		
	Gu et al. 2009	34	70	18	60	3.8%	1.62 [1.03, 2.55]		
	Han et al. 2021	25	56	13	49	2.7%	1.68 [0.97, 2.92]		
	Huang et al. 2013	17	28	14	34	2.5%	1.47 [0.89, 2.43]		
	Lei et al. 2018	18	29	14	29	2.7%	1.29 [0.80, 2.06]		· ·
	Liu 2000	18	23	11	20	2.3%	1.42 [0.91, 2.23]		<b>—</b>
	Lu and Zhao 2011	19	31	12	30	2.4%	1.53 [0.91, 2.58]	,	
	Qian et al. 2020	19	35	10	36	1.9%	1.95 [1.06, 3.59]		
	Qin et al. 1998	13	27	10	29	1.9%	1.40 [0.74, 2.64]		· · ·
	Shi et al. 2019	14	21	9	22	1.7%	1.63 [0.91, 2.93]		
	Song et al. 2015	19	56	10	55	2.0%	1.87 [0.96, 3.64]		
	Tao et al. 2021	20	38	11	38	2.2%	1.82 [1.02, 3.25]		
	Wang et al. 2018	10	30	6	30	1.2%	1.67 [0.69, 4.00]		· · ·
	Wang et al. 2012	19	31	12	30	2.4%	1.53 [0.91, 2.58]		· · ·
	Wu et al. 2018	20	31	11	31	2.2%	1.82 [1.06, 3.13]		
	Xu et al. 2018	45	50	39	50	7.7%	1.15 [0.97, 1.37]		-
	Yu et al. 2020	37	45	28	45	5.5%	1.32 [1.01, 1.72]		<b>⊢</b> −
	Zeng et al. 2011	15	25	10	24	2.0%	1.44 [0.81. 2.55]	-	
	Zhang 1997	11	16	7	17	1.3%	1.67 [0.87. 3.22]	-	
	Zhang et al. 2019	32	40	24	33	5.2%	1.10 [0.85. 1.43]	-	<b>+</b> −−
	Zhang et al. 2013	11	13	4	12	0.8%	2.54 [1.10. 5.84]		
	Zhao et al. 2012	15	21	9	20	1.8%	1.59 [0.91, 2.76]		<u>├</u>
	Zhao et al. 1999	14	18	6	12	1.4%	1.56 [0.84, 2.88]	-	
	Zhao et al. 2018	15	35	12	35	2.4%	1.25 [0.69. 2.27]	_	
	Zheng et al. 1999	19	20	17	23	3.1%	1.29 [0.99, 1.67]		
	Zheng et al. 2014	97	120	64	121	12.5%	1.53 [1.26, 1.85]		-
	Zhong and Hao 2019	21	30	12	30	2.4%	1.75 [1.06, 2.88]		
	Zhou 2010	16	36	7	21	1.7%	1.33 [0.66, 2.70]		
	Zhou et al. 2009	13	44	7	40	1.4%	1.69 [0.75, 3.81]	_	
	Total (95% CI)		1278		1229	100.0%	1.48 [1.38, 1.60]		♦
	Total events	772		502					
	Heterogeneity: Chi <sup>2</sup> = 2	24.47, df = 3	34 (P = 0	).89); l <sup>2</sup> =	0%			+ +	
								0.05 0.2	1 5 20
	l est for overall effect: 4	Z = 10.10 (F	P < 0.00	001)				Equation [control]	Equation [experimentel]
	l est for overall effect: a	Z = 10.10 (F	<sup>o</sup> < 0.00	001)				Favours [control]	Favours [experimental]
в	l est for overall effect: a	Experime	o < 0.00 ental	001) Contr	ol		Risk Ratio	Favours [control]	Favours [experimental] Ratio
в	Study or Subgroup	Experim Events	P < 0.00 ental Total	001) Contr Events	ol Total	Weight	Risk Ratio M-H, Fixed, 95% C	Favours [control] Risk	Favours [experimental] Ratio ed, 95% Cl
в	Study or Subgroup Bi et al. 2012	2 = 10.10 (F Experime Events 20	P < 0.000 ental <u>Total</u> 25	001) Contr <u>Events</u> 19	ol <u>Total</u> 24	Weight 2.6%	Risk Ratio <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34]	Favours [control] Risk M-H, Fix	Favours [experimental] Ratio ed, 95% Cl
в	Study or Subgroup Bi et al. 2012 Chen et al. 2005	2 = 10.10 (F Experime Events 20 29	P < 0.00 ental <u>Total</u> 25 33	001) Contr <u>Events</u> 19 24	ol <u>Total</u> 24 30	Weight 2.6% 3.4%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37]	Favours [control] Risk	Favours [experimental] Ratio ed, 95% Cl
в	Bi et al. 2012 Chen et al. 2012 Chen et al. 2012	2 = 10.10 (F Experime Events 20 29 9	P < 0.00 ental <u>Total</u> 25 33 18	001) Contr Events 19 24 7	ol <u>Total</u> 24 30 18	Weight 2.6% 3.4% 0.9%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70]	Favours [control] Risk	Favours [experimental] Ratio ed. 95% Cl
в	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2012 Chen et al. 2008	2 = 10.10 (F Experime Events 20 29 9 57	P < 0.00 ental <u>Total</u> 25 33 18 68	001) Contr Events 19 24 7 54	ol <u>Total</u> 24 30 18 71	Weight 2.6% 3.4% 0.9% 7.1%	<b>Risk Ratio</b> <u>M-H. Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30]	Favours [control] Risk M-H, Fix	Favours [experimental] Ratio ed. 95% Cl
в	Bi et al. 2012 Chen et al. 2012 Chen et al. 2015 Chen et al. 2012 Chen et al. 2012 Chen et al. 2018 Fan et al. 2011	2 = 10.10 (F Experime Events 20 29 9 57 30	P < 0.00 ental <u>Total</u> 25 33 18 68 41	001) Contr Events 19 24 7 54 27	ol <u>Total</u> 24 30 18 71 40	Weight 2.6% 3.4% 0.9% 7.1% 3.7%	Risk Ratio <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44]	Favours [control] Risk M-H. Fix	Favours [experimental] Ratio ed. 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Chen et al. 2018 Fan et al. 2011 Fan and Wang 2021	Z = 10.10 (F Experime Events 20 29 9 57 30 34	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>Total</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> </ul>	001) Contr Events 19 24 7 54 27 32	ol <u>Total</u> 24 30 18 71 40 36	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3%	Risk Ratio <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.7] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22]	Favours [control] Risk M-H. Fix	Favours [experimental] Ratio ed. 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2008 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013	2 = 10.10 (F Experime 20 29 9 57 30 34 34 34	<ul> <li>2 &lt; 0.000</li> <li>ental</li> <li>Total</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> </ul>	001) Contr Events 19 24 7 54 27 32 19	ol <u>Total</u> 24 30 18 71 40 36 34	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed. 95% Cl
В	Bi et al. 2012 Chen et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009	2 = 10.10 (F Experime Events 20 29 9 57 30 34 34 65	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>Total</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> </ul>	001) Contr Events 19 24 7 54 27 32 19 42	ol <u>Total</u> 24 30 18 71 40 36 34 60	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 6.1%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.42] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed. 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2021	2 = 10.10 (F Experime 20 29 9 57 30 34 34 65 48	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>Total</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> </ul>	001) Contr Events 19 24 7 54 27 54 27 32 19 42 32	ol <u>Total</u> 24 30 18 71 40 36 34 60 49	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 6.1% 4.6%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.29 [0.61, 2.70] 1.29 [0.61, 2.70] 1.00 [0.82, 1.44] 1.06 [0.92, 1.42] 1.06 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65]	Favours [control] Risk I M-H. Fix 	Favours [experimental] Ratio ed. 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2010 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2021 Huang et al. 2013	2 = 10.10 (F Experime 20 29 9 57 30 34 34 34 65 48 21	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> <li>28</li> </ul>	001) Contr Events 19 24 7 54 27 32 19 42 32 32 22	ol Total 24 30 18 71 40 36 34 60 49 34	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 6.1% 4.6% 2.7%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61]	Favours [control] Risk M-H. Fix 	Favours [experimental] Ratio ed. 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2021 Huang et al. 2013 Lei et al. 2018	2 = 10.10 (F Experim 20 29 9 57 30 34 34 34 65 48 21 25	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> <li>28</li> <li>29</li> </ul>	001) Contr Events 19 24 7 54 27 32 19 42 32 32 32 22 21	ol <u>Total</u> 24 30 18 71 40 36 34 60 49 34 29	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 6.1% 4.6% 2.7% 2.8%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.61 [0.84, 1.61] 1.19 [0.91, 1.56]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed. 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2013 Lei et al. 2013 Lu and Zhao 2011	2 = 10.10 (F Experim 20 29 9 57 30 34 34 65 48 21 25 24	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> <li>28</li> <li>29</li> <li>31</li> </ul>	001) Contr Events 19 24 7 54 27 32 19 42 32 22 22 21 19	ol <u>Total</u> 24 30 18 71 40 36 34 60 49 34 29 30	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 6.1% 4.6% 2.7% 2.8% 2.6%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.29 [0.61, 2.70] 1.29 [0.61, 2.70] 1.00 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70]	Favours [control] Risk I M-H. Fix 	Favours [experimental] Ratio ed, 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2010 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2013 Lei et al. 2013 Lu and Zhao 2011 Qian et al. 2020	2 = 10.10 (F Experim 20 29 9 57 30 34 34 34 65 48 21 25 24 29 22 22 22 25 24 29	ental <u>Total</u> 25 33 18 68 41 36 38 70 56 28 29 31 35	001) Contr Events 19 24 7 54 27 32 19 42 32 22 21 19 22 21 19 21	ol <u>Total</u> 24 30 18 71 40 36 34 60 49 34 29 30 36	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 6.1% 4.6% 2.7% 2.8% 2.8% 2.8%	<b>Risk Ratio</b> <u>M-H. Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.92, 1.20] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed. 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2018 Fan et al. 2011 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2021 Huang et al. 2013 Lui et al. 2021 Qian et al. 2020 Qin et al. 1998	2 = 10.10 (F Experim: <u>Events</u> 20 29 9 57 30 34 65 48 21 25 24 29 25	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>Total</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> <li>28</li> <li>29</li> <li>31</li> <li>35</li> <li>27</li> </ul>	001) Contr Events 19 24 7 54 27 32 19 42 32 22 21 19 21 21	ol <u>Total</u> 24 30 18 71 40 36 34 60 49 34 29 30 36 29	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 4.6% 2.7% 2.8% 2.6% 2.8% 2.7%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.29 [0.61, 2.70] 1.10 [0.93, 1.37] 1.08 [0.82, 1.42] 1.60 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.61 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.22 [1.00, 1.64]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed. 95% C1
в	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2019 Lu and Zhao 2011 Qian et al. 2020 Qin et al. 2019	2 = 10.10 (F Experime 20 29 9 57 30 34 65 48 21 25 24 29 25 24 29 25 19	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> <li>28</li> <li>29</li> <li>31</li> <li>35</li> <li>27</li> <li>21</li> </ul>	001) Contr Events 19 24 7 54 27 32 19 42 32 22 21 19 42 32 22 21 19 21 21 21 21 21 19 24 32 22 21 19 24 32 22 21 19 24 27 32 22 21 32 22 21 32 22 32 22 32 22 32 32 32 32	ol <u>Total</u> 24 30 18 71 40 36 34 60 49 34 29 30 36 29 22	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 4.6% 2.8% 2.8% 2.8% 2.6% 2.8% 2.5%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.29 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.28 [1.00, 1.64] 1.05 [0.84, 1.30]	Favours [control] Risk <u>M-H, Fix</u> 	Favours [experimental] Ratio ed, 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2010 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2019 Lu and Zhao 2011 Qian et al. 2020 Qin et al. 1998 Shi et al. 2015	2 = 10.10 (F Experim 20 29 9 57 30 34 34 34 65 48 21 25 24 4 29 25 19 9 19 19	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>Total</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> <li>28</li> <li>29</li> <li>31</li> <li>35</li> <li>27</li> <li>21</li> <li>56</li> </ul>	001) Contr Events 19 24 7 32 19 42 32 27 32 19 42 32 21 19 21 21 19 21 21 30 30	ol <u>Total</u> 24 30 18 71 40 36 34 60 49 34 29 30 36 29 22 55	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 4.3% 4.6% 2.7% 2.8% 2.8% 2.8% 2.8% 2.5% 4.1%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.02 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.82, 1.44] 1.66 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.82 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79]	Favours [control] Risk M-H. Fix 	Favours [experimental] Ratio ed. 95% Cl
В	Study or Subgroup           Bi et al. 2012           Chen et al. 2005           Chen et al. 2012           Chen et al. 2015           Chen et al. 2014           Fan et al. 2017           Fan et al. 2018           Fan et al. 2011           Feng and Zhao 2013           Gu et al. 2009           Han et al. 2021           Huang et al. 2013           Lei et al. 2018           Lu and Zhao 2011           Qian et al. 2020           Qin et al. 2019           Song et al. 2015           Tao et al. 2021	2 = 10.10 (F Experim: <u>Events</u> 20 29 9 57 30 34 34 65 48 8 21 25 24 29 25 19 41 1 30	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> <li>28</li> <li>29</li> <li>31</li> <li>35</li> <li>27</li> <li>21</li> <li>36</li> <li>38</li> </ul>	001) Contr Events 19 24 7 54 27 32 19 42 32 22 21 19 21 21 19 30 21	ol Total 24 30 18 71 40 36 34 60 49 34 29 30 36 29 30 36 29 22 55 38	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 6.1% 4.6% 2.7% 2.8% 2.6% 2.8% 4.1% 4.1% 2.8%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70] 1.08 [0.82, 1.42] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.28 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.01, 1.99]	Favours [control] Risk M-H. Fix 	Favours [experimental] Ratio ed. 95% C1
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2019 Han et al. 2019 Lu and Zhao 2011 Qian et al. 2019 Shi et al. 2019 Shi et al. 2019 Sang et al. 2015 Tao et al. 2018	2 = 10.10 (F Experime Events 20 29 9 57 30 34 34 34 65 54 88 21 25 24 29 25 19 41 30 27	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>411</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> <li>28</li> <li>29</li> <li>31</li> <li>35</li> <li>27</li> <li>21</li> <li>56</li> <li>38</li> <li>31</li> <li>36</li> <li>38</li> <li>31</li> </ul>	001) Contr Events 19 24 7 54 27 32 19 42 32 22 21 19 21 21 21 19 30 21 22 21 21 21 21 21 22 21 21	ol Total 24 30 18 71 40 36 34 49 34 29 30 36 29 22 55 88 30	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 6.1% 2.8% 2.8% 2.8% 2.8% 2.5% 4.1% 2.8% 3.0%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22] 1.30 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.22 [0.84, 1.61] 1.22 [0.84, 1.61] 1.22 [1.04, 1.95] 1.22 [1.00, 1.64] 1.05 [0.84, 1.30] 1.24 [1.01, 1.79] 1.43 [1.03, 1.99] 1.43 [1.03, 1.99] 1.51 [0.92, 1.53]	Favours [control] Risk <u>I M-H, Fix</u> 	Favours [experimental] Ratio ed, 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2005 Chen et al. 2008 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2019 Han et al. 2013 Lei et al. 2013 Lu and Zhao 2011 Qian et al. 2020 Qin et al. 1998 Shi et al. 2015 Tao et al. 2021 Wang et al. 2018 Wang et al. 2018	2 = 10.10 (F Experime 20 29 9 57 30 34 34 34 48 21 25 24 48 21 25 24 29 25 19 41 30 27 27	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> <li>27</li> <li>21</li> <li>56</li> <li>38</li> <li>31</li> <li>31</li> </ul>	001) Contr Events 19 24 7 54 27 32 19 42 32 21 19 21 21 19 30 21 22 22 22 22 22 22 22 22 22	ol Total 24 30 18 71 40 36 34 49 34 29 30 60 29 22 55 53 8 38 30 30	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 4.6% 2.7% 6.1% 4.6% 2.7% 2.8% 2.8% 2.6% 2.8% 4.1% 2.8% 3.0%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.02 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.82, 1.44] 1.66 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.82 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed. 95% Cl
В	Study or Subgroup           Bi et al. 2012           Chen et al. 2005           Chen et al. 2012           Chen et al. 2015           Chen et al. 2012           Chen et al. 2014           Fan et al. 2014           Fan et al. 2017           Feng and Zhao 2013           Gu et al. 2009           Han et al. 2021           Huang et al. 2013           Lei et al. 2021           Uian et al. 2020           Qin et al. 2020           Qin et al. 2020           Qin et al. 2015           Tao et al. 2021           Wang et al. 2018           Wang et al. 2012           Wu et al. 2012	2 = 10.10 (F Experim: <u>Events</u> 20 29 9 57 30 34 34 65 48 21 25 24 29 25 24 29 25 19 41 30 27 27 28	<ul> <li>&lt; 0.000</li> <li>ental</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>41</li> <li>36</li> <li>38</li> <li>70</li> <li>56</li> <li>28</li> <li>29</li> <li>31</li> <li>35</li> <li>27</li> <li>21</li> <li>56</li> <li>38</li> <li>31</li> <li>31</li> <li>31</li> </ul>	001) Contr Events 19 244 7 54 27 322 19 42 322 21 19 22 21 19 21 21 21 21 21 21 21 21 21 22 22	ol Total 24 30 18 71 40 36 34 60 49 34 29 30 36 29 22 55 38 30 30 30 31	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 2.8% 2.6% 2.8% 2.8% 2.5% 4.1% 2.8% 3.0% 3.0% 3.0%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.19 [0.94, 1.61] 1.19 [0.94, 1.61] 1.29 [1.04, 1.95] 1.28 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.39 [1.03, 1.99] 1.19 [0.92, 1.53] 1.40 [1.05, 1.58]	Favours [control] Risk M-H. Fix 	Favours [experimental] Ratio ed. 95% C1
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2019 Han et al. 2019 Lu and Zhao 2011 Qin et al. 2019 Shi et al. 2019 Shi et al. 2019 Song et al. 2015 Tao et al. 2011 Wang et al. 2018 Wang et al. 2018 Wu et al. 2018 Xu et al. 2018	2 = 10.10 (F Experime Events 20 29 9 57 30 34 34 34 65 55 48 21 25 24 29 25 19 41 30 27 28 48	ental <u>Total</u> 25 33 18 8 8 41 36 41 36 38 41 36 56 28 29 31 35 27 21 35 27 21 35 38 31 31 35 27 31 31 35 35 37 31 35 37 37 37 37 37 37 37 37 37 37	001) Contr Events 19 24 7 54 27 32 19 42 22 22 21 19 22 21 19 21 21 21 21 21 21 22 22 21 21	ol Total 24 30 18 71 40 36 34 60 49 30 36 29 22 29 30 36 29 22 25 55 38 30 30 30 30 55 55 55 55 55 55 55 55 55 55 55 55 55	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 4.3% 2.7% 2.8% 2.8% 2.8% 2.8% 2.5% 4.1% 2.8% 3.0% 3.0% 3.0% 3.0% 2.7%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.01 [0.8, 1.37] 1.29 [0.61, 2.70] 1.00 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.61 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.28 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.01, 1.79] 1.49 [0.92, 1.53] 1.19 [0.92, 1.53] 1.09 [1.92, 1.53] 1.04 [1.05, 1.86] 1.04 [1.05, 1.86] 1.04 [0.94, 1.15]	Favours [control] Risk M-H. Fix 	Favours [experimental] Ratio ed, 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2020 Han et al. 2021 Huang et al. 2013 Lei et al. 2013 Lei et al. 2013 Lu and Zhao 2011 Qian et al. 2020 Qin et al. 1998 Shi et al. 2015 Tao et al. 2015 Tao et al. 2011 Wang et al. 2012 Wu et al. 2018 Xu et al. 2018 Xu et al. 2020	2 = 10.10 (F Experime 20 29 9 57 30 34 34 34 34 655 24 48 21 25 24 29 25 19 41 30 27 27 28 48 43	ental <u>Total</u> 25 33 18 68 41 36 68 41 38 70 56 68 29 31 35 27 21 56 38 38 37 21 56 38 31 31 35 27 21 5 33 38 38 70 56 56 57 57 57 57 57 57 57 57 57 57	001) Contr Events 19 244 7 54 27 32 32 32 32 32 22 22 21 19 21 21 21 21 21 21 21 21 22 21 22 21 22 21 24 21 24 27 24 27 32 22 22 22 22 21 24 27 24 27 24 27 24 27 24 27 24 27 24 27 24 27 24 27 22 22 22 22 21 21 21 21 21 21	ol Total 24 30 18 71 40 36 34 60 49 34 29 30 36 29 22 5 53 8 8 30 30 30 30 31 5 54 55 54 55 55 55 55 55 55 55 55 55 5	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 2.8% 2.6% 2.8% 2.8% 2.8% 2.5% 4.1% 2.8% 3.0% 3.0% 5.4%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.02 [0.88, 1.37] 1.29 [0.61, 2.70] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.82 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.04 [0.95, 1.21]	Favours [control] Risk M-H_Fix 	Favours [experimental] Ratio ed. 95% C1
В	Study or Subgroup           Bi et al. 2012           Chen et al. 2005           Chen et al. 2012           Chen et al. 2015           Chen et al. 2012           Chen et al. 2014           Fan et al. 2011           Fan et al. 2011           Fan and Wang 2021           Feng and Zhao 2013           Gu et al. 2009           Han et al. 2013           Lei et al. 2018           Lu and Zhao 2011           Qian et al. 2020           Qin et al. 2019           Shi et al. 2015           Tao et al. 2015           Yao et al. 2011           Wang et al. 2018           Yu et al. 2018           Yu et al. 2018           Yu et al. 2011	2 = 10.10 (F Experim: <u>Events</u> 20 29 9 57 300 34 34 65 48 21 25 24 48 29 25 19 41 300 27 27 27 27 28 48 43 20 29 25 29 25 29 25 29 25 29 29 25 29 20 29 29 29 20 29 29 29 29 20 29 29 29 29 29 20 29 29 29 20 29 29 29 20 29 29 20 29 20 29 29 20 29 20 29 20 29 20 29 20 29 20 20 20 20 20 20 20 20 20 20	• < 0.000           ental         Total           Total         25           33         38           48         41           36         38           70         5           5         28           29         31           35         27           21         35           38         31           31         31           50         38           31         31           50         45	001) Contr Events 19 244 7 54 27 32 19 42 32 22 21 19 21 21 21 21 21 21 21 21 21 21	ol Total 24 30 18 71 40 36 34 49 34 29 30 36 39 22 25 55 38 30 30 30 30 30 31 50 42 4	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 3.0% 3.0% 3.0% 5.4% 5.4%	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.93, 1.30] 1.08 [0.82, 1.42] 1.60 [1.17, 2.20] 1.33 [1.14, 1.65] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.28 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.04 [0.94, 1.15] 1.07 [0.95, 1.21] 1.07 [0.76, 1.24]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed. 95% C1
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2019 Han et al. 2021 Huang et al. 2013 Lei et al. 2019 Shi et al. 2019 Shi et al. 2019 Song et al. 2015 Tao et al. 2011 Wang et al. 2018 Wang et al. 2018 Wu et al. 2018 Yu et al. 2018 Yu et al. 2018 Yu et al. 2019	2 = 10.10 (F Experime Events 20 29 9 57 30 34 34 34 65 55 48 21 25 24 29 25 19 41 30 27 28 48 43 20 37	ental <u>Total</u> 255 333 18 68 41 38 70 56 68 29 31 35 27 21 56 38 33 31 31 31 35 27 21 56 38 39 31 35 35 27 27 21 56 36 38 38 38 38 38 38 38 38 38 38	001) Contr Events 19 24 7 54 27 32 19 42 22 22 21 19 42 22 22 21 19 30 21 21 21 21 21 21 22 22 20 46 40 21 9 42 22 22 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 42 20 20 42 20 20 42 20 20 20 20 20 20 20 20 20 2	ol Total 24 300 36 34 49 34 29 30 30 36 30 30 36 29 22 29 22 55 55 38 30 30 30 31 50 45 24 33	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 4.6% 2.8% 2.8% 2.8% 2.8% 2.5% 4.1% 2.8% 3.0% 3.0% 3.0% 5.4% 5.4% 2.8%	Risk Ratio M-H, Fixed, 95% C 1.01 [0.76, 1.34] 1.01 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.61 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.28 [1.00, 1.64] 1.55 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.01, 1.79] 1.49 [0.92, 1.53] 1.19 [0.92, 1.53] 1.19 [0.92, 1.53] 1.00 [1.04, 1.15] 1.07 [0.95, 1.21] 1.01 [0.76, 1.34] 1.71 [0.66, 1.43]	Favours [control] Risk I M-H_Fix 	Favours [experimental] Ratio ed, 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2007 Chen et al. 2008 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2019 Han et al. 2020 Han et al. 2020 Han et al. 2013 Lei et al. 2018 Lu and Zhao 2011 Qian et al. 2018 Lu and Zhao 2011 Qian et al. 2019 Song et al. 2015 Tao et al. 2015 Tao et al. 2015 Wang et al. 2015 Wang et al. 2011 Wang et al. 2012 Wu et al. 2018 Xu et al. 2018 Xu et al. 2020 Zeng et al. 2020 Zeng et al. 2011 Zhang et al. 2019 Zhang et al. 2019	2 = 10.10 (F Experime 20 29 9 57 30 34 34 34 34 655 24 48 21 25 29 25 19 41 30 27 28 48 30 27 28 43 30 27 27 28 43 30 29 31 30 34 34 34 34 34 34 34 34 34 34	<ul> <li>a &lt; 0.000</li> <li>ental</li> <li>Total</li> <li>25</li> <li>25</li> <li>33</li> <li>18</li> <li>68</li> <li>68</li> <li>38</li> <li>70</li> <li>56</li> <li>28</li> <li>29</li> <li>35</li> <li>26</li> <li>27</li> <li>27</li> <li>26</li> <li>38</li> <li>31</li> <li>32</li> <li>32</li> <li>34</li> <li>35</li> <li>36</li> <li>36</li> <li>37</li> <li>38</li> <li>38</li> <li>39</li> <li>30</li> <li>31</li> <li>31</li> <li>32</li> <li>32</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>31</li> <li>32</li> <li>34</li> <li>34</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>38</li> <li>39</li> <li>30</li> <li>31</li> <li>31</li> <li>32</li> <li>34</li> <li>34</li> <li>34</li> <li>34</li> <li>34</li> <li>34</li> <li>34</li> <li>34</li> <li>34<!--</td--><td>001) Contr Events 19 24 7 54 27 32 32 32 32 32 32 32 32 32 32</td><td>ol Total 24 30 18 18 40 34 40 49 34 29 30 30 30 30 30 30 30 30 31 50 50 45 24 33 31 20 45 50 22 55 50 22 55 50 30 30 30 50 50 50 31 30 50 50 50 50 50 50 50 50 50 50 50 50 50</td><td>Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 2.8% 2.7% 2.8% 2.8% 2.8% 2.5% 4.1% 2.8% 3.0% 2.5% 4.1% 2.5% 4.1% 2.5% 3.0% 2.7% 3.0% 2.7% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0</td><td><b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.01 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.82 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.07 [0.95, 1.21] 1.01 [0.76, 1.34] 1.17 [0.96, 1.43] 1.17 [0.96, 1.43]</td><td>Favours [control] Risk M-H_Fix </td><td>Favours [experimental] Ratio ed. 95% C1</td></li></ul>	001) Contr Events 19 24 7 54 27 32 32 32 32 32 32 32 32 32 32	ol Total 24 30 18 18 40 34 40 49 34 29 30 30 30 30 30 30 30 30 31 50 50 45 24 33 31 20 45 50 22 55 50 22 55 50 30 30 30 50 50 50 31 30 50 50 50 50 50 50 50 50 50 50 50 50 50	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 2.8% 2.7% 2.8% 2.8% 2.8% 2.5% 4.1% 2.8% 3.0% 2.5% 4.1% 2.5% 4.1% 2.5% 3.0% 2.7% 3.0% 2.7% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.01 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.82 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.07 [0.95, 1.21] 1.01 [0.76, 1.34] 1.17 [0.96, 1.43] 1.17 [0.96, 1.43]	Favours [control] Risk M-H_Fix 	Favours [experimental] Ratio ed. 95% C1
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2013 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2019 Han et al. 2021 Huang et al. 2013 Lei et al. 2018 Lu and Zhao 2011 Qian et al. 2020 Qin et al. 2019 Song et al. 2015 Tao et al. 2011 Wang et al. 2018 Xu et al. 2011 Zhang et al. 2011 Zhang et al. 2013 Zhao et al. 2013	2 = 10.10 (F Experim: <u>Events</u> 20 29 9 57 300 34 34 65 48 21 25 24 48 29 25 19 41 300 27 27 28 48 43 20 30 30 29 19 10 29 29 25 19 41 30 30 29 29 29 25 19 41 21 29 25 19 41 30 30 30 30 30 27 27 25 28 48 48 30 30 30 30 30 30 30 30 30 30	• < 0.000           ental         Total           Total         25           33         38           68         41           36         38           70         5           5         26           38         36           38         38           70         5           28         29           31         35           277         21           36         38           311         31           50         45           45         40           13         25           40         13           21         32	001) Contr Events 19 244 7 54 27 32 19 42 32 22 21 19 21 21 21 21 21 21 21 21 21 21	ol Total 24 300 34 60 49 34 60 49 34 29 30 36 29 30 36 29 30 36 29 30 36 29 30 36 29 30 36 29 30 36 29 30 36 40 34 40 34 40 34 40 34 40 34 40 34 55 55 38 30 30 30 31 55 55 38 30 30 30 30 30 30 30 30 30 30	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0	<b>Risk Ratio</b> <u>M-H. Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.93, 1.30] 1.08 [0.82, 1.42] 1.60 [1.17, 2.20] 1.33 [1.11, 1.56] 1.31 [1.04, 1.65] 1.31 [1.04, 1.65] 1.26 [1.04, 1.61] 1.19 [0.91, 1.56] 1.22 [1.04, 1.95] 1.28 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.04 [0.94, 1.15] 1.07 [0.6, 1.34] 1.17 [0.96, 1.43] 1.17 [0.96, 1.43] 1.11 [0.82, 1.49]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed. 95% C1
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Chen et al. 2012 Chen et al. 2014 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2019 Han et al. 2021 Huang et al. 2013 Lei et al. 2018 Lu and Zhao 2011 Qin et al. 2019 Song et al. 2015 Tao et al. 2012 Wang et al. 2018 Wang et al. 2018 Yu et al. 2011 Zhang et al. 2013 Zhao et al. 2012 Zhao et al. 2013	2 = 10.10 (F Experime Events 2 20 29 9 57 30 34 34 34 65 55 48 21 25 24 29 25 19 41 30 0 27 27 28 48 43 20 37 19 57 19 11 10 10 10 10 10 10 10 10 10	• • • 0.000           ental         Total           1         255         33           33         18         88           38         41         36           36         38         7           56         62         88           29         31         35           27         21         56           38         31         31           31         31         31           35         27         40           45         25         40           13         21         35	001) Contr Events 19 24 7 54 27 32 19 42 22 22 21 19 42 22 22 21 19 30 21 21 21 21 21 21 21 19 42 22 20 46 40 19 42 22 22 20 42 19 42 27 19 42 27 19 42 27 20 22 22 21 19 42 22 22 21 19 42 27 19 42 22 22 21 19 42 22 22 21 19 42 27 19 42 27 22 22 21 19 42 27 21 21 21 21 21 21 21 21 21 21	ol Total 24 36 37 36 36 34 400 49 30 36 36 39 29 22 25 55 38 30 30 30 30 30 45 24 33 30 30 30 30 30 30 30 30 30	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 4.6% 2.8% 2.6% 2.8% 2.8% 2.5% 4.1% 2.8% 3.0% 3.0% 3.0% 5.4% 2.6% 3.8% 1.4% 2.8%	Risk Ratio M-H, Fixed, 95% C 1.01 [0.76, 1.34] 1.01 [0.88, 1.37] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22] 1.30 [1.11, 1.58] 1.31 [1.04, 1.65] 1.31 [1.04, 1.65] 1.34 [1.04, 1.65] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.28 [1.00, 1.64] 1.55 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.01, 1.79] 1.49 [0.92, 1.53] 1.19 [0.92, 1.53] 1.00 [1.04, 1.15] 1.07 [0.95, 1.21] 1.01 [0.76, 1.34] 1.17 [0.96, 1.43] 1.11 [0.82, 1.49] 1.77 [0.8, 1.42] 1.77 [0.8, 1.43] 1.71 [0.86, 1.44] 1.71 [0.86, 1.44] 1.7	Favours [control] Risk I M-H_Fix 	Favours [experimental] Ratio ed, 95% Cl
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2008 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2019 Han et al. 2021 Huang et al. 2013 Lei et al. 2013 Lei et al. 2018 Lu and Zhao 2011 Qian et al. 2020 Qin et al. 1998 Shi et al. 2015 Tao et al. 2015 Tao et al. 2012 Wang et al. 2015 Tao et al. 2012 Wang et al. 2011 Zhang et al. 2020 Zeng et al. 2011 Zhang et al. 2012 Zhao et al. 2012 Zhao et al. 2012 Zhao et al. 2012 Zhao et al. 2012	2 = 10.10 (F Experime 20 29 9 57 30 34 34 34 35 48 21 25 24 29 25 19 41 30 27 28 48 30 27 28 43 20 37 12 29 25 19 29 25 19 29 29 25 19 29 29 20 29 29 20 29 29 20 29 29 20 29 29 20 29 20 29 29 20 29 29 20 29 20 29 20 29 20 29 20 29 20 29 20 20 29 20 20 29 20 20 20 20 20 20 20 20 20 20	ental <u>Total</u> 25 25 25 25 25 25 26 38 8 8 8 8 8 8 8 8 8 8 8 8 8	001) Contr Events 19 24 7 54 27 32 32 32 32 32 32 32 32 32 32	ol <u>Total</u> 24 300 18 71 400 34 600 49 30 36 49 29 300 36 39 29 22 25 55 38 300 300 310 310 45 24 29 300 300 316 34 402 300 36 34 402 300 36 34 402 300 36 36 36 36 36 36 36 36 36 36	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 2.8% 2.7% 2.8% 2.8% 2.8% 2.5% 4.1% 2.8% 3.0% 2.5% 4.1% 2.5% 3.0% 2.7% 6.2% 3.8% 1.4% 2.6% 3.8% 2.6% 3.8% 2.6% 3.0% 2.7% 4.3% 2.6% 4.3% 2.6% 4.3% 2.7% 4.3% 2.6% 4.3% 2.7% 4.3% 2.7% 4.3% 2.7% 4.3% 2.7% 4.3% 2.7% 4.3% 2.7% 4.3% 2.7% 4.3% 2.7% 4.3% 2.7% 4.3% 2.7% 4.3% 2.7% 2.8% 2.8% 2.7% 4.3% 2.7% 4.3% 2.7% 4.3% 2.7% 2.8% 2.8% 2.5% 4.3% 2.5% 4.3% 2.7% 4.3% 2.7% 4.3% 2.8% 2.5% 4.3% 2.5% 4.3% 2.6% 2.6% 2.8% 2.5% 4.3% 2.5% 4.3% 2.6% 2.6% 2.5% 4.3% 2.5% 4.3% 2.6% 2.6% 2.6% 2.5% 4.3% 4.3% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.00 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.82 [1.00, 1.64] 1.55 [0.84, 1.30] 1.43 [1.01, 1.79] 1.43 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.04 [0.94, 1.15] 1.07 [0.95, 1.21] 1.01 [0.76, 1.34] 1.17 [0.96, 1.42] 1.17 [0.96, 1.42] 1.19 [0.96, 1.42] 1.14 [1.04, 2.00]	Favours [control] Risk M-H_Fix 	Favours [experimental] Ratio ed. 95% C1
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2005 Chen et al. 2012 Chen et al. 2012 Chen et al. 2010 Fan et al. 2011 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2019 Huang et al. 2013 Lei et al. 2018 Lu and Zhao 2011 Qian et al. 2020 Qin et al. 2019 Song et al. 2019 Song et al. 2011 Wang et al. 2011 Wang et al. 2018 Xu et al. 2011 Zhang et al. 2011 Zhang et al. 2011 Zhao et al. 2012 Zhao et al. 2013 Zhao et al. 2013 Zhao et al. 2018	2 = 10.10 (F Experim: <u>Events</u> 20 29 9 57 300 34 34 65 48 21 25 24 29 25 19 41 300 27 27 28 48 43 20 30 30 29 19 41 30 29 25 19 41 30 30 29 29 25 19 41 30 29 25 19 41 30 29 25 19 41 25 24 25 29 25 19 41 30 30 30 30 34 34 34 34 35 25 26 29 25 29 25 29 25 29 25 29 25 29 25 19 41 30 30 30 30 30 30 30 30 30 30	• < 0.000           ental         Total           Total         25           33         33           18         68           48         41           36         38           70         5           5         27           21         35           277         21           38         31           31         31           50         40           13         25           40         13           355         30	001) Contr Events 19 244 7 54 27 32 19 42 32 22 21 19 42 32 22 21 19 21 21 21 21 21 21 21 21 21 21	ol Total 24 36 37 36 34 49 34 39 30 30 30 30 30 32 35 33 32 35 30 35 30 35 30 35 36 35 35 35 35 35 35 35 35 35 35	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0	<b>Risk Ratio</b> <u>M-H. Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.09 [0.61, 2.70] 1.09 [0.61, 2.70] 1.09 [0.61, 2.70] 1.08 [0.82, 1.42] 1.60 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.04, 1.65] 1.31 [1.04, 1.65] 1.31 [1.04, 1.65] 1.26 [1.04, 1.61] 1.9 [0.91, 1.56] 1.22 [1.04, 1.95] 1.28 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.49 [0.92, 1.53] 1.49 [0.92, 1.53] 1.40 [1.05, 1.86] 1.04 [0.94, 1.15] 1.07 [0.61, 1.44] 1.17 [0.96, 1.43] 1.17 [0.96, 1.43] 1.19 [0.96, 1.46] 1.44 [1.04, 2.00] 1.21 [0.44, 1.05] 1.24 [1.04, 2.00] 1.21 [0.44, 2.00]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed. 95% C1
В	Study or Subgroup Bi et al. 2012 Chen et al. 2005 Chen et al. 2012 Chen et al. 2013 Gu et al. 2014 Fan and Wang 2021 Feng and Zhao 2013 Gu et al. 2009 Han et al. 2019 Lu and Zhao 2011 Qian et al. 2019 Song et al. 2019 Song et al. 2019 Song et al. 2015 Tao et al. 2018 Wang et al. 2018 Wu et al. 2018 Yu et al. 2018 Zhag et al. 2011 Zhao et al. 2012 Zhao et al. 2013 Zhao et al. 2013 Zhao et al. 2013 Zhao gu et al. 2013 Zhao et al. 2019 Zhou 2010 Zhuy et al. 2019 Zhou 2010	2 = 10.10 (F Experime Events 2 20 29 9 57 30 34 34 34 65 55 48 21 25 29 25 19 41 30 27 28 48 43 20 37 19 41 30 27 28 48 21 29 25 19 41 30 27 28 29 29 29 29 29 29 29 29 29 29	ental Total 255 333 18 68 88 41 36 38 41 36 38 41 36 56 66 28 9 31 35 27 21 56 63 88 31 31 31 31 31 31 32 33 33 33 33 33 33 38 41 36 38 38 38 38 38 38 38 38 38 38	001) Contr Events 199 24 7 54 27 32 32 32 32 32 32 22 22 21 19 42 32 32 22 21 19 42 32 22 22 21 19 42 27 32 32 32 32 32 32 32 32 32 32	ol Total 24 30 18 71 40 36 34 49 34 29 30 36 29 33 30 30 30 31 55 55 38 30 30 30 31 55 55 24 45 22 22 55 53 83 00 30 30 30 30 30 30 30 30 30 30 30 30	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 4.6% 2.8% 2.8% 2.8% 2.8% 2.5% 4.1% 2.8% 3.0% 3.0% 3.0% 5.4% 2.6% 3.0% 3.0% 3.0% 3.0% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4	Risk Ratio M-H, Fixed, 95% C 1.01 [0.76, 1.34] 1.01 [0.88, 1.37] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.28 [1.00, 1.64] 1.5 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.01, 1.79] 1.43 [1.03, 1.83] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.04 [0.94, 1.15] 1.07 [0.95, 1.21] 1.01 [0.76, 1.34] 1.17 [0.96, 1.43] 1.11 [0.82, 1.49] 1.77 [0.8, 1.42] 1.19 [0.96, 1.46] 1.41 [1.04, 2.00] 1.24 [0.87, 1.92] 1.9 [0.96, 1.46] 1.41 [1.04, 2.00] 1.21 [0.86, 1.46] 1.44 [1.04, 2.00] 1.21 [0.86, 1.46] 1.44 [1.04, 2.00] 1.21 [0.86, 1.46] 1.44 [1.04, 2.00] 1.21 [0.86, 1.46] 1.44 [1.04, 2.00] 1.27 [0.87, 1.92] 1.9 [0.87, 1.92] 1.9 [0.87, 1.92] 1.9 [0.96, 1.46] 1.44 [1.04, 2.00] 1.21 [0.86, 1.70] 1.21 [0	Favours [control] Risk I M-H_Fix 	Favours [experimental] Ratio ed, 95% Cl
В	Study or Subgroup           Bi et al. 2012           Chen et al. 2005           Chen et al. 2005           Chen et al. 2005           Chen et al. 2012           Chen et al. 2008           Fan et al. 2011           Fan et al. 2011           Fan et al. 2011           Gu et al. 2020           Han et al. 2021           Huang et al. 2013           Lei et al. 2014           Uan et al. 2020           Qin et al. 2018           Song et al. 2015           Tao et al. 2014           Wang et al. 2015           Yu et al. 2018           Yu et al. 2018           Yu et al. 2018           Yu et al. 2019           Zhang et al. 2011           Zhang et al. 2012           Zhao et al. 2013           Zhao et al. 2012           Zhao et al. 2012           Zhao et al. 2013           Zhao et al. 2013	2 = 10.10 (F Experime 20 29 9 57 30 34 34 35 48 21 25 48 21 25 29 25 19 41 30 27 28 43 20 37 12 28 43 20 29 25 19 29 25 19 29 25 19 29 25 19 21 25 29 25 19 21 25 29 25 19 25 19 27 28 43 20 29 25 19 27 28 43 20 27 28 43 20 27 28 43 20 27 28 43 20 27 28 43 20 29 25 26 29 25 19 27 28 43 20 27 28 28 29 20 27 28 29 20 27 28 29 20 27 28 29 20 27 28 29 20 27 28 28 29 20 27 28 29 20 27 28 29 20 20 27 28 29 20 27 28 29 20 20 27 28 28 29 20 20 20 20 27 28 28 29 20 20 20 20 27 28 28 29 20 20 20 20 20 20 20 20 20 20	• < 0.000           ental           Total           2 < 5           3           18           68           8           68           36           36           37           56           28           29           35           277           28           29           35           26           36           31           50           40           31           21           35           36           311           50           25           400           31           32           21           35           36           40           36           40           35           36           36	001) Contr Events 19 24 7 54 27 32 32 32 32 32 32 32 32 32 32	ol Total 24 30 18 71 40 36 34 49 34 29 30 36 30 36 30 30 31 55 55 38 30 30 31 55 55 24 33 30 30 31 55 55 38 30 30 31 55 55 38 30 30 31 55 55 38 30 30 30 31 55 55 36 30 30 30 30 30 30 30 30 30 30 30 30 30	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 2.8% 2.7% 2.8% 2.8% 2.7% 2.8% 3.0% 2.5% 4.1% 2.8% 3.0% 2.7% 6.2% 3.0% 2.7% 6.2% 3.0% 2.6% 3.8% 2.6% 3.8% 2.6% 3.8% 2.6% 2.6% 3.8% 2.7% 4.3% 2.7% 4.3% 2.8% 2.7% 2.8% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.00 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.28 [1.00, 1.64] 1.05 [0.84, 1.30] 1.43 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.04 [0.94, 1.15] 1.07 [0.95, 1.21] 1.01 [0.76, 1.34] 1.17 [0.86, 1.42] 1.44 [1.04, 2.00] 1.24 [0.86, 1.70] 1.24 [0.86, 1.70] 1.27 [0.87, 1.86]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed. 95% C1
В	Test for overall effect: .           Study or Subgroup           Bi et al. 2012           Chen et al. 2005           Chen et al. 2008           Fan et al. 2012           Feng and Zhao 2013           Gu et al. 2009           Han et al. 2013           Lei et al. 2018           Lu and Zhao 2011           Qian et al. 2020           Qin et al. 2018           Song et al. 2015           Tao et al. 2021           Wang et al. 2015           Tao et al. 2014           Wang et al. 2015           Yu et al. 2018           Yu et al. 2018           Yu et al. 2018           Yu et al. 2010           Zhang et al. 2011           Zhang et al. 2013           Zhao et al. 2013           Zhao et al. 2013           Zhao et al. 2010           Zhou 2010           Zhou 2010           Zhou et al. 2009	2 = 10.10 (F Experime 20 29 9 57 30 34 34 34 65 48 21 25 24 429 25 29 25 19 41 30 27 27 28 48 43 30 27 27 28 48 43 20 37 29 25 29 25 29 25 19 29 25 24 41 30 29 25 24 41 25 24 41 25 24 41 25 24 41 30 27 27 28 48 32 20 27 28 48 32 20 28 28 28 28 28 28 28 28 28 28	• < 0.000           ental           Total           2 5           33           18           68           41           36           38           41           36           38           70           56           28           29           31           35           27           21           56           38           311           311           311           311           311           311           311           311           311           311           311           311           311           311           311           312           313           311           312           313           314           315           316           317           318           319           311           313	001) Contr Events 19 244 7 54 27 32 32 32 32 32 32 32 32 32 32	ol Total 24 36 37 49 34 49 34 29 34 29 36 29 222 55 38 30 31 50 43 31 50 43 31 50 43 31 50 31 50 31 50 31 50 55 38 30 31 50 55 38 30 31 55 55 38 30 31 55 55 38 30 31 55 55 38 30 31 55 55 38 30 31 55 55 38 30 31 55 55 38 30 31 55 55 38 30 31 50 55 55 38 30 30 31 50 55 55 38 30 30 31 50 55 55 38 30 31 50 55 55 38 30 30 31 50 55 55 38 30 30 31 50 55 55 38 30 30 31 50 55 55 55 38 30 30 31 50 55 53 53 55 53 38 30 30 31 50 55 53 30 31 50 55 53 30 30 31 50 55 53 30 30 31 50 50 53 53 53 53 53 53 53 53 53 53	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 2.8% 2.8% 2.8% 2.8% 2.8% 3.0% 3.0% 5.4% 3.0% 3.0% 3.0% 3.0% 3.0% 3.8% 1.4% 3.8% 1.4% 3.6% 2.2% 3.6% 2.2% 3.6% 3.8% 1.4% 3.6% 2.2% 3.8% 3.8% 3.8% 3.8% 3.2% 3.6% 3.8% 3.4% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7	<b>Risk Ratio</b> <u>M-H. Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.09 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.93, 1.30] 1.08 [0.82, 1.42] 1.60 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.65] 1.22 [0.88, 1.70] 1.42 [1.04, 1.65] 1.22 [0.88, 1.70] 1.42 [1.04, 1.65] 1.22 [0.8, 1.70] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.07 [0.95, 1.21] 1.01 [0.76, 1.34] 1.17 [0.96, 1.43] 1.17 [0.96, 1.43] 1.19 [0.92, 1.42] 1.19 [0.96, 1.42] 1.19 [0.96, 1.42] 1.19 [0.96, 1.42] 1.21 [0.86, 1.70] 1.27 [0.87, 1.86] 1.20 [1.15, 1.26] 1.20 [1.15, 1.26]	Favours [control] Risk M-H.Fix 	Favours [experimental] Ratio ed. 95% C1
В	Study or Subgroup           Bi et al. 2012           Chen et al. 2005           Chen et al. 2012           Chen et al. 2013           Gu et al. 2014           Fan et al. 2014           Huang et al. 2013           Lei et al. 2014           Uang et al. 2013           Lei et al. 2014           Qin et al. 2019           Song et al. 2015           Tao et al. 2014           Wang et al. 2015           Yu et al. 2014           Wang et al. 2015           Yu et al. 2014           Yu et al. 2012           Wu et al. 2014           Yu et al. 2013           Zhao et al. 2011           Zhao et al. 2012           Zhao et al. 2013           Zhao et al. 2014	2 = 10.10 (F Experime Events 2 20 29 9 57 30 34 34 34 65 55 48 21 25 24 29 25 19 41 30 0 27 27 28 48 43 20 0 29 25 19 41 30 0 27 29 25 29 25 29 25 29 25 29 25 29 29 20 29 20 29 20 29 20 20 20 20 20 20 20 20 20 20	• • • 0.000           ental           Total           25           33           38           33           18           68           38           41           36           38           77           21           56           38           31           32           33           30           36           44           1082	001) Contr Events 199 24 27 54 27 32 19 42 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 42 22 21 19 21 21 22 21 19 21 21 21 21 21 21 21 21 21 21	ol Total 24 30 18 71 40 36 49 34 29 30 36 29 22 55 53 8 8 30 30 30 31 50 45 24 45 22 55 53 8 30 30 22 25 55 38 30 30 22 45 30 30 22 45 30 30 46 49 30 49 30 49 30 49 30 49 30 49 30 49 30 30 60 49 30 49 30 30 49 30 30 49 30 30 49 30 30 30 49 30 30 30 49 30 30 30 49 30 30 30 30 30 30 30 30 30 30 30 30 30	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 2.6% 2.8% 2.6% 2.8% 2.7% 2.8% 2.5% 4.1% 2.8% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 2.5% 4.1% 2.8% 2.5% 4.1% 2.8% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.10 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.93, 1.30] 1.08 [0.82, 1.44] 1.06 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.31 [1.04, 1.65] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.28 [1.00, 1.64] 1.05 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.03, 1.99] 1.49 [0.92, 1.53] 1.40 [1.05, 1.28] 1.04 [0.94, 1.15] 1.07 [0.95, 1.21] 1.01 [0.76, 1.34] 1.17 [0.96, 1.43] 1.17 [0.96, 1.43] 1.17 [0.96, 1.44] 1.17 [0.96, 1.44] 1.17 [0.96, 1.44] 1.44 [1.04, 2.00] 1.21 [0.86, 1.70] 1.27 [0.87, 1.86] <b>1.20 [1.15, 1.26]</b>	Favours [control] Risk M-H.Fix 	Favours [experimental] Ratio ed, 95% Cl
В	Study or Subgroup           Bi et al. 2012           Chen et al. 2005           Chen et al. 2012           Chen et al. 2012           Chen et al. 2012           Chen et al. 2012           Chen et al. 2011           Fan et al. 2011           Fan et al. 2013           Gu et al. 2013           Lei et al. 2013           Lei et al. 2013           Lei et al. 2014           Vang et al. 2013           Gin et al. 2020           Qin et al. 2015           Song et al. 2015           Tao et al. 2011           Wang et al. 2013           Wang et al. 2014           Wang et al. 2017           Wu et al. 2018           Yu et al. 2019           Zhang et al. 2011           Zhao et al. 2012           Zhao et al. 2013           Zhao et al. 2012           Zhao et al. 2013           Zhao et al. 2013           Zhao et al. 2019           Zhou 2010           Zhou 2010           Zhou et al. 2009           Total (95% CI)           Total events	2 = 10.10 (F Experime 20 29 9 57 30 34 34 34 65 55 48 21 25 19 41 30 27 28 43 20 29 25 19 21 29 25 19 21 29 25 29 21 29 20 29 20 29 20 29 20 29 20 29 20 29 20 29 20 29 20 29 20 29 20 20 29 20 20 29 20 20 20 20 20 20 20 20 20 20	ental Total 25 25 25 25 26 38 8 8 8 8 8 8 8 8 8 8 8 8 8	0011) Contr Events 19 24 7 54 27 32 32 32 32 32 221 19 21 21 19 21 21 21 21 21 21 21 21 22 20 40 40 19 21 21 21 21 21 21 21 21 21 21	ol Total 24 30 18 71 40 36 34 49 34 29 30 36 29 30 36 29 22 255 55 38 8 30 30 31 50 55 24 33 12 20 35 21 40 94 94 94 94	Weight 2.6% 3.4% 0.9% 7.1% 4.3% 2.7% 4.6% 2.8% 2.8% 2.8% 2.8% 3.0% 2.5% 4.1% 2.8% 3.0% 2.5% 4.1% 2.8% 3.0% 2.6% 3.0% 2.4% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8	<b>Risk Ratio</b> <u>M-H, Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.00 [0.88, 1.37] 1.29 [0.61, 2.70] 1.00 [0.82, 1.24] 1.60 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.58] 1.31 [1.04, 1.65] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.95] 1.28 [1.00, 1.64] 1.25 [0.84, 1.30] 1.34 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.00 [1.05, 1.86] 1.04 [0.94, 1.15] 1.07 [0.95, 1.21] 1.01 [0.76, 1.34] 1.17 [0.82, 1.49] 1.17 [0.82, 1.49] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.41 [1.04, 2.00] 1.24 [1.04, 2.00] 1.24 [1.04, 2.00] 1.27 [0.87, 1.86] 1.20 [1.15, 1.26]	Favours [control] Risk M-H, Fix 	Favours [experimental] Ratio ed, 95% Cl
В	Test for overall effect: .           Study or Subgroup           Bi et al. 2012           Chen et al. 2005           Chen et al. 2008           Fan et al. 2012           Feng and Zhao 2013           Gu et al. 2009           Han et al. 2013           Lei et al. 2013           Lei et al. 2013           Lei et al. 2014           Qian et al. 2020           Qin et al. 2015           Tao et al. 2015           Tao et al. 2015           Yu et al. 2018           Wu et al. 2018           Yu et al. 2018           Yu et al. 2019           Zhang et al. 2011           Zhang et al. 2012           Zhao et al. 2012           Zhao et al. 2013           Zhao et al. 2010           Zhou gand Hao 2010           Zhou gand Hao 2010           Zhou et al. 2009           Total (95% CI)           Total events           Heterogeneity: Chi <sup>2</sup> = 3	2 = 10.10 (F Experim: <u>Events</u> 20 29 9 57 30 34 34 34 35 48 21 25 24 48 21 25 24 29 25 19 41 30 27 28 48 31 20 29 57 30 0 34 34 34 35 24 29 25 19 57 30 0 34 34 34 35 26 29 29 29 25 19 29 29 25 19 29 29 25 29 29 25 29 25 29 25 29 25 29 25 29 25 29 25 29 25 29 25 29 25 19 21 29 25 29 25 19 21 29 25 19 21 25 24 41 30 27 28 48 48 21 25 24 41 30 27 27 28 43 30 27 27 28 43 32 20 29 25 19 25 19 25 19 25 19 25 19 26 19 27 28 43 30 27 27 28 43 32 20 27 28 43 32 26 29 27 28 43 32 26 29 27 28 43 32 26 29 29 25 19 27 28 43 32 26 29 27 28 43 32 26 29 29 27 28 43 32 26 29 28 43 32 26 29 28 43 32 26 29 28 43 32 26 29 28 32 26 29 28 32 26 29 28 32 26 29 28 32 26 29 28 32 26 28 32 26 28 28 32 26 28 28 31 27 28 28 28 28 28 28 28 28 28 28	2 < 0.000 ental Total Total 2 5 2 5 3 6 3 7 3 8 3 8 3 8 3 8 3 8 3 8 3 8 3 8 3 8 3 8 3 9 3 6 3 8 3 1 3 1 3 6 3 8 3 1	001) Contr Events 19 244 7 7 32 19 42 32 32 32 22 22 21 19 21 21 21 21 21 21 21 21 21 21	ol Total 24 30 18 71 49 34 49 34 29 36 29 22 29 22 29 22 29 36 36 30 30 31 50 43 30 31 50 32 49 32 32 32 33 30 36 36 37 49 36 36 36 37 49 36 36 36 36 36 37 49 36 36 36 36 36 36 36 36 36 36	Weight 2.6% 3.4% 0.9% 7.1% 3.7% 4.3% 2.7% 2.8% 2.6% 2.8% 2.6% 3.0% 2.7% 6.1% 2.8% 3.0% 2.7% 6.2% 5.4% 3.8% 1.4% 2.6% 3.8% 1.4% 2.8% 3.6% 2.2% 3.6% 2.4% 3.6% 2.4% 3.6% 2.4% 3.6% 2.4% 3.6% 2.4% 3.6% 2.4% 3.6% 2.4% 3.6% 2.8% 3.6% 2.8% 3.6% 3.8% 3.6% 3.8% 3.6% 3.8% 3.8% 3.8% 3.7% 3.6% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7	<b>Risk Ratio</b> <u>M-H. Fixed, 95% C</u> 1.01 [0.76, 1.34] 1.09 [0.88, 1.37] 1.29 [0.61, 2.70] 1.10 [0.93, 1.30] 1.08 [0.82, 1.44] 1.66 [0.92, 1.22] 1.60 [1.17, 2.20] 1.33 [1.11, 1.55] 1.16 [0.84, 1.61] 1.19 [0.91, 1.56] 1.22 [0.88, 1.70] 1.42 [1.04, 1.65] 1.22 [0.88, 1.70] 1.42 [1.04, 1.65] 1.28 [1.00, 1.64] 1.05 [0.84, 1.30] 1.42 [1.04, 1.30] 1.34 [1.01, 1.79] 1.43 [1.03, 1.99] 1.19 [0.92, 1.53] 1.40 [1.05, 1.86] 1.07 [10,5, 1.21] 1.01 [0.76, 1.34] 1.17 [0.81, 1.42] 1.19 [0.98, 1.46] 1.44 [1.04, 2.00] 1.21 [0.86, 1.70] 1.27 [0.87, 1.86] 1.20 [1.15, 1.26]	Favours [control] Risk M-H.Fix 	Favours [experimental] Ratio ed. 95% Cl

Forest plot displaying the efficacy of elemene on the response rate (A) and DCR (B) of cancer patients treated with chemotherapy.

(Vaitkiene et al., 2019). A higher score on these measures indicates better overall health status and greater tolerance for the side effects of treatment. The pooled data showed that elemene was able to elevate the

rate of improvement and stability in quality of life, as well as KPS, among chemotherapy patients (WMD:1.31, 95% CI:1.12-1.53, p = 0.0006, Figure 7A; WMD:8.04, 95% CI:3.87–12.21, *p* = 0.0002;



Thrombocytopenia, Anemia, **(I)** Phlebitis.

Figure 7B). Sensitivity analysis and TSA analysis showed that the results were stable and conclusive (Supplementary Figures S2Q-R; Supplementary Figure S6O), despite the heterogeneity observed in the included clinical trials ( $I^2 = 58\%$ , p = 0.01, Figure 7A;  $I^2 = 82\%$ , p = 0.0007; Figure 7B). Meta-regression analysis discovered CR was associated with quality-of-life improvement and stability rate (p = 0.085, Supplementary Table S1). Subgroup analysis revealed that elemene was more likely to increase the rate of improvement and stability in quality of life among cancer patients treated with cisplatin and docetaxel/ vinorelbine, FOLFOX4, CTV, or paclitaxel and carboplatin (WMD: 1.15, 95% CI:1.00-1.32, p = 0.05; WMD:1.19, 95% CI:1.28-2.88, p = 0.002; WMD:1.41, 95% CI:1.06-1.88, p = 0.02; WMD:1.76, 95% CI: 1.03-3.01, p = 0.04, Supplementary Figure S4J). Its publication bias was shown in Supplementary Figure S4H. Additionally, subgroup analysis of KPS based on CNE indicated that the combination of elemene for a maximum of 6 cycles was more effective in enhancing KPS (WMD: 10.09, 95% CI:6.99–13.20, p < 0.00001, Supplementary Figure S4K). LCSS was often used to evaluate the quality of life of lung cancer. As expected, elemene could lower the scores of anorexia, cough, dyspnea, hemoptysis, and pain in lung cancer patients receiving chemotherapy (p < 0.0001), and these studies of these outcomes were homogeneity ( $I^2 = 0\%$ , p = 1.00;  $I^2 = 0\%$ , p = 0.99;  $I^2 = 0\%$ , p = 0.99;  $I^2 = 0\%$ , p = 1.00;  $I^2 = 0\%$ , p = 0.99; Figure 7C). Therefore, combining with elemene could improve the quality of life among chemotherapy patients.

#### The efficacy of elemene on the survival rate of lung cancer patients treated with chemotherapy

One-year and 2-year survival rates were reported in 7 and 5 clinical studies involving 560 and 358 lung cancer patients,



and (D) CD4<sup>+</sup>/CD8<sup>+</sup> T cells.

respectively (Figure 8). Fixed-effects models were applied because there was no significant heterogeneity for either 1year or 2-year survival rate ( $I^2 = 0\%$ , p = 0.93;  $I^2 = 0\%$ , p = 0.67, Figure 8). The results demonstrated that the addition of elemene to chemotherapy significantly increased the 1-year and 2-year survival rates of lung cancer patients (RR:1.34, 95% CI: 1.15–1.56, p = 0.0002; RR:1.57, 95% CI:1.14–2.16, p = 0.006, Figure 8). Sensitivity and meta-regression analysis confirmed that the pooled results would not be changed by any study or variable included in this article (Supplementary Figures S2S, T; p > 0.1; Supplementary Table S1). Based on TSA analysis, the cumulative Z curves reached the RIS or TSA boundaries, demonstrating the results were conclusive (Supplementary Figures S6P, Q).



#### Quality of evidence

GRADEpro software was used to summarize the quality of evidence for the outcomes provided in Supplementary Table S2.

The quality of evidence was moderate in 6 outcomes, low in 11, and very low in 8, which indicated that the inference of combination of elemene on response rate, DCR, leukopenia (III-IV), hemoglobin reduction, neurotoxicity, and phlebitis was more credible.

	Experime	ental	Contro			RISK Ratio	RISK Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
21.1.1 1-year surviva	al rate						
Chen et al. 2005	13	33	9	30	7.5%	1.31 [0.66, 2.62]	
Chen et al. 2008	29	68	21	71	16.3%	1.44 [0.92, 2.27]	<b></b>
an and Wang 2021	29	36	21	36	16.7%	1.38 [1.00, 1.90]	
_iu 2000	10	23	9	20	7.6%	0.97 [0.49, 1.89]	
Xu et al. 2018	41	50	31	50	24.6%	1.32 [1.03, 1.70]	
Zhang et al. 2019	27	40	14	33	12.2%	1.59 [1.01, 2.50]	
Zhao et al. 2018	23	35	19	35	15.1%	1.21 [0.82, 1.78]	
Subtotal (95% CI)		285		275	100.0%	1.34 [1.15, 1.56]	
Total events	172		124				
Heterogeneity: Chi <sup>2</sup> =	1.88, df = 6	(P = 0.9)	93); l <sup>2</sup> = 0 <sup>6</sup>	%			
Test for overall effect:	: Z = 3.71 (P	= 0.000	02)				
21.1.2 2-year surviva	al rate						
an and Wang 2021	17	36	8	36	18.7%	2.13 [1.05, 4.29]	
_iu 2000	5	23	4	20	10.0%	1.09 [0.34, 3.50]	
		50	19	50	44.3%	1.26 [0.80, 1.99]	
Xu et al. 2018	24				45 00/	0 00 10 00 4 701	
Xu et al. 2018 Zhang et al. 2019	24 15	40	6	33	15.3%	2.06 [0.90, 4.72]	
Xu et al. 2018 Zhang et al. 2019 Zhao et al. 2018	24 15 8	40 35	6 5	33 35	15.3%	2.06 [0.90, 4.72] 1.60 [0.58, 4.41]	
Xu et al. 2018 Zhang et al. 2019 Zhao et al. 2018 <b>Subtotal (95% CI)</b>	24 15 8	40 35 <b>184</b>	6 5	33 35 174	15.3% 11.7% <b>100.0%</b>	2.06 [0.90, 4.72] 1.60 [0.58, 4.41] <b>1.57 [1.14, 2.16]</b>	•
Xu et al. 2018 Zhang et al. 2019 Zhao et al. 2018 Subtotal (95% CI) Total events	24 15 8 69	40 35 184	6 5 42	33 35 174	15.3% 11.7% <b>100.0%</b>	1.60 [0.58, 4.41] 1.57 [1.14, 2.16]	•
Xu et al. 2018 Zhang et al. 2019 Zhao et al. 2018 Subtotal (95% CI) Total events Heterogeneity: Chi <sup>2</sup> =	24 15 8 69 2.38, df = 4	40 35 184 (P = 0.6	6 5 42 67); I <sup>2</sup> = 0 <sup>0</sup>	33 35 174 %	15.3% 11.7% <b>100.0%</b>	2.06 [0.90, 4.72] 1.60 [0.58, 4.41] 1.57 [1.14, 2.16]	•
Xu et al. 2018 Zhang et al. 2019 Zhao et al. 2018 <b>Subtotal (95% CI)</b> Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect:	24 15 8 69 2.38, df = 4 Z = 2.77 (P	40 35 184 (P = 0.6	6 5 42 67); I <sup>2</sup> = 0 <sup>0</sup> 6)	33 35 174 %	15.3% 11.7% 100.0%	2.06 [0.90, 4.72] 1.60 [0.58, 4.41] 1.57 [1.14, 2.16]	•
Xu et al. 2018 Zhang et al. 2019 Zhao et al. 2018 <b>Subtotal (95% CI)</b> Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect:	24 15 8 69 2.38, df = 4 Z = 2.77 (P	40 35 184 (P = 0.6	6 5 42 67); I <sup>2</sup> = 0 6)	33 35 174 %	15.3% 11.7% 100.0%	2.06 [0.90, 4.72] 1.60 [0.58, 4.41] 1.57 [1.14, 2.16]	•
Xu et al. 2018 Zhang et al. 2019 Zhao et al. 2018 <b>Subtotal (95% CI)</b> Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect:	24 15 8 69 2.38, df = 4 : Z = 2.77 (P	40 35 184 (P = 0.0	6 5 42 67); I <sup>2</sup> = 0 <sup>6</sup> 6)	33 35 174 %	15.3% 11.7% 100.0%	2.06 [0.90, 4.72] 1.60 [0.58, 4.41] 1.57 [1.14, 2.16]	
Xu et al. 2018 Zhang et al. 2019 Zhao et al. 2018 <b>Subtotal (95% CI)</b> Total events Heterogeneity: Chi <sup>2</sup> = Fest for overall effect:	24 15 8 69 2.38, df = 4 : Z = 2.77 (P	40 35 184 (P = 0.6	6 5 42 67); l <sup>2</sup> = 0 <sup>0</sup> 8)	33 35 174 %	15.3% 11.7% 100.0%	2.06 [0.90, 4.72] 1.60 [0.58, 4.41] 1.57 [1.14, 2.16]	
Ku et al. 2018 Zhang et al. 2019 Zhao et al. 2018 <b>Subtotal (95% CI)</b> Fotal events Heterogeneity: Chi <sup>2</sup> = Fest for overall effect:	24 15 8 69 2.38, df = 4 : Z = 2.77 (P	40 35 184 (P = 0.6 = 0.006	6 5 42 67); I <sup>2</sup> = 0 <sup>0</sup> 8)	33 35 174 %	15.3% 11.7% 100.0%	2.06 [0.90, 4.72] 1.60 [0.58, 4.41] 1.57 [1.14, 2.16]	0.01 0.1 1 10 10 Favours [control] Favours [experimental]

# Discussion

The intricate nature of cancer cells continues to pose a significant challenge for researchers and medical professionals. Besides efficacy, the quality of life and psychological state of patients should also be fully considered during cancer treatment. Chemotherapy is a common treatment for cancer patients, but the side effects and multi-drug resistance problems that come with it cannot be ignored. Certain studies have indicated that chemotherapeutic drugs can induce alterations in the pulmonary microenvironment, thereby promoting the metastasis of cancer cells (Keklikoglou et al., 2019; Middleton et al., 2021). Therefore, adjuvant therapy is often used to achieve improved therapeutic outcomes and mitigate the problems caused by chemotherapy.

Elemene injection and elemene oral emulsion are applied in clinical in China for more than 20 years, the principal component,  $\beta$ -elemene has attracted researchers' attention, and the molecular mechanisms for anticancer, reversing chemotherapeutic resistance, and alleviating neuropathic pain are revealed, involving Cyclin-dependent kinases, glycolytic kinases, ATP-binding cassette transporters, N6methyladenosine methyltransferase, NMYC downstream-regulated gene 2, etc., (Zhao et al., 2011; Zhang et al., 2013b; Zhai et al., 2019; Liu et al., 2020; Ma et al., 2021). Most of all, there were no reported severe adverse effects so far. However, the appearance of a few dissenting voices has caught our attention. Whether the combination of elemene can enhance the efficacy and reduce the toxicity of different chemotherapy regimens for different cancers. For a variety of side effects caused by different chemotherapy regimens, whether the combination of elemene has a relief effect. In this study, a comprehensive literature search and reference selection were carried out to ensure that no relevant clinical studies were missed. GRADE system and TSA were used to assess the strength of evidence and robustness of our results. To ensure the accuracy of the results, we performed sensitivity, meta-regression, and subgroup analysis to find the source of heterogeneity and further analyzed the effect of the combination according to CNE, CT, CR, etc. Our study integrated 38 clinical studies encompassing a total of 2709 patients diagnosed with 12 different types of cancer and treated with 35 distinct chemotherapy regimens. The results of our study indicate that elemene could increase the efficacy, quality of life, immune function, and survival rate of patients undergoing chemotherapy, while also reducing the prevalence of most chemotherapy-induced side effects. However, significant improvements in response rate and DCR existed only when the cycle number of elemene was less than 6. Although regression analyses showed that the effects of elemene on most side effects, immune function, quality of life, and survival rate were not significantly influenced by SZ, CR, CT, TT, DE, CNE, and DDE, subgroup analysis indicated that CNE and TT were the primary contributors to heterogeneity in these findings. The effect of elemene on anemia and CD8<sup>+</sup> T is influenced by CT, while the quality of life improvement and stability rate is affected by CR. Nevertheless, both GRADE and TSA suggested us more high-quality studies are needed to included obtain more precise conclusions. Unexpectedly, we found that prolonged administration of elemene leads to enhanced immune function, albeit with a potential decline in the improvement of the incidence of side effects of chemotherapy. However, due to the low quality of most of the outcomes on immune function and adverse effects, this conclusion needs to be supported by additional clinical data and deserves further attention. Notably, concomitant use of elemene in chemotherapy-treated cancer patients increased the incidence of

phlebitis, but the result may alter with subsequent, more adequate clinical data. The quality of life of cancer patients was increased when elemene combined with cisplatin and docetaxel/vinorelbine, FOLFOX4, CTV, or paclitaxel and carboplatin, or no more than 6 cycles. In general, the treatment time and the number of cycles of elemene should be strictly controlled.

Regretfully, this study presents both strengths and limitations. Although all included studies were clinical trials, the quality of them was not high, with a majority lacking information on double-blind procedures. The existence of publication bias may also lead to bias in the evaluation of intervention effects. Our analysis discovered that the elemene combination therapy was regional, as elemene injection and elemene oral emulsion are independently developed and used in China. Consequently, the effect on chemotherapy patients in different countries or regions remains uncertain. What's more, we found that the combination was mainly used in patients with gastric cancer and lung cancer, and the sample sizes of patients with breast cancer, liver cancer, acute myelocytic leukemia, colorectal cancer, and Non-Hodgkin lymphoma were so small that some results merely indicated tendencies without reaching statistical significance. Moreover, changes in serumrelated indicators in cancer patients treated with chemotherapy have rarely been reported in studies. In addition, there are few studies about drug-resistant patients. Due to the limited number of studies included for some of the outcomes, it is difficult to ensure the accuracy of the conclusions. Therefore, the recommended plan in this study may not be optimal, however, it will clear up the confusion about the clinical use of this drug and provide a reference for the treatment of some cancer patients.

It is worth noting that while elemene injection and elemene oral emulsion share the same ingredient, the drug description indicates a notable reduction in the applicability of the oral emulsion, rendering it more suitable for the adjuvant treatment of esophageal cancer and gastric cancer (Bai et al., 2021). However, the difference in efficacy between elemene injection and elemene oral emulsion is still unknown. In our study, there were only two clinical studies that used elemene oral emulsion. The comparisons could not be made due to the lack of identical combination groups. Meanwhile, the absence of published clinical studies and systematic reviews on the comparative efficacy of elemene injection versus elemene oral emulsion for cancer treatment suggests that this is a good point for an in-depth study. The poor aqueous solubility and bioavailability of elemene limit its clinical application. Researchers focused on the secondary development of its major active ingredient,  $\beta$ -elemene to solve the problems of poor aqueous solubility, low bioavailability, and severe phlebitis, as well as to improve antitumor efficacy (Chen et al., 2017; Zhai et al., 2018). Although the structure modification and development of the delivery system have improved the antitumor activity and bioavailability of  $\beta$ -elemene to some extent, it is still in the biological experimental stage, and no new products have entered the clinic. Therefore, adjusting the treatment regimen may remain the main solution for now.

# Conclusion

Combination with elemene could increase the efficacy, quality of life, immune function, and survival rate of chemotherapy patients, and reduce the prevalence of most chemotherapy-induced side effects. A shorter duration and fewer cycles are recommended for its combination.

# Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: PubMed, Cochrane Library, Web of Science, EMBASE, CKNI, Wan Fang, and VIP database, which can be obtained by searching according to the names and accession numbers.

# Author contributions

YP: Conceptualization, data extraction, data assessment and analysis, writing-review and editing. PW: Data extraction, data assessment and analysis. LZ: Search literature. CW: Search literature. YW: Supervision, data curation. All authors contributed to the article and approved the submitted version.

# Funding

This study is supported by the Science and Technology Development Fund of Nanjing Medical University (NMUB20210033).

# Acknowledgments

All authors express thankfulness to the Science and Technology Development Fund of Nanjing Medical University for supporting this study, and also thanks Renjun Gu for the help with registration.

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1185987/ full#supplementary-material

#### 10.3389/fphar.2023.1185987

# References

Bai, Z., Yao, C., Zhu, J., Xie, Y., Ye, X. Y., Bai, R., et al. (2021). Anti-Tumor drug discovery based on natural product  $\beta$ -elemene: Anti-tumor mechanisms and structural modification. *Molecules* 26, 1499. doi:10.3390/molecules26061499

Bi, Y., Zeng, D., and Ling, Y. (2012). The clinical research of elemene emulsion combined with FOLFOX4 regimen in the treatment of advanced gastric carcinoma. *Chinese-German J. Clin. Onco.* 11, 336–339. doi:10.1007/s10330-012-0968-y

Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 21, 3233. doi:10.3390/ijms21093233

Chang, Z., Gao, M., Zhang, W., Song, L., Jia, Y., and Qin, Y. (2017). Beta-elemene treatment is associated with improved outcomes of patients with esophageal squamous cell carcinoma. *Surg. Oncol.* 26, 333–337. doi:10.1016/j.suronc.2017.07.002

Chen, H., Yang, Z., Zhang, M., and Chen, Z. (2012). Clinical observation of elemene combined with paclitaxel/tegafur in the treatment of advanced esophageal carcinoma. *Anhui Med. Pharm.* 16, 1679–1681. doi:10.3969/j.issn.1009-6469.2012.11.054

Chen, J., Wang, T., Xu, S., Zhang, P., Lin, A., Wu, L., et al. (2017). Discovery of novel antitumor nitric oxide-donating  $\beta$ -elemene hybrids through inhibiting the PI3K/Akt pathway. *Eur. J. Med. Chem.* 135, 414–423. doi:10.1016/j.ejmech.2017.04.045

Chen, N., Li, H., Tan, S., and Yang, F. (2005). Observation of weekly dose of docetaxel combined with elemene emulsion in the treatment of 68 cases of advanced non-small cell lung cancer. *Chin. J. Clin. Oncol.* 32, 896–897. doi:10.3969/j.issn.1000-8179.2005.15.019

Chen, Y., Zhuang, W., and Liu, Y. (2008). Efficacy observation of elemene combined with DC regimen in the treatment of advanced non-small cell lung cancer. *Shandong Med. J.* 48, 54–55. doi:10.3969/j.issn.1002-266X.2008.30.024

Chen, Z., Li, J., Liu, W., Zhang, S., and Sun, H. (2022). Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer. *World J. Clin. Cases* 10, 1498–1507. doi:10.12998/wjcc.v10.i5.1498

Cheng, G., Li, L., Li, Q., Lian, S., Chu, H., Ding, Y., et al. (2022).  $\beta$ -elemene suppresses tumor metabolism and stem cell-like properties of non-small cell lung cancer cells by regulating PI3K/AKT/mTOR signaling. *Am. J. Cancer Res.* 12, 1535–1555.

Diasio, R. B., and Offer, S. M. (2022). Testing for dihydropyrimidine dehydrogenase deficiency to individualize 5-fluorouracil therapy. *Cancers (Basel)* 14, 3207. doi:10.3390/ cancers14133207

Fan, C., Dai, H., and Chu, Y. (2011). Clinical effect of elemene combined with chemotherapy in the treatment of 81 cases of advanced gastric cancer. *Chin. J. Clin. Oncol.* 38, 112–113. doi:10.3969/j.issn.1000-8179.2011.02.014

Fan, L., Strasser-Weippl, K., Li, J. J., St Louis, J., Finkelstein, D. M., Yu, K. D., et al. (2014). Breast cancer in China. *Lancet Oncol.* 15, e279–e289. doi:10.1016/S1470-2045(13)70567-9

Fan, Y., and Wang, R. (2021). Effects of Elemene Injection combined with chemotherapy and targeted drugs on the quality of life and immune function in patients with advanced non-small cell lung cancer. *World J. Integr. Tradit. West Med.* 16, 119–122+127. doi:10.13935/j.cnki.sjzx.210126

Feng, A., and Zhao, P. (2013). Elemene Emulsion plus CHOPE chemotherapy in treatment of intractable or recurrent non-hodgkin lymphoma. *J. Pract. Onco* 28, 320–322. doi:10.13267/j.cnki.syzlzz.2013.03.002

Gu, H., Yang, L., and Chen, Z. (2009). Effect of elemene injection combined with chemotherapy on improving quality of life in patients with advanced malignant tumor. *J. Hebei Med. Univ.* 30, 941–942. doi:10.3969/j.issn.1007-3205.2009.09.029

Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., et al. (2011). GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J. Clin. Epidemiol. 64, 383–394. doi:10.1016/j.jclinepi.2010.04.026

Han, J., Guan, Y., and Zhang, J. (2021). Clinical observation of Elemene Injection combined with TAC chemotherapy regimen in treatment of advanced breast cancer. *Drugs Clin.* 36, 111–116. doi:10.7501/j.issn.1674-5515.2021.01.022

Higgins, J. P., and Thompson, S. G. (2002). Quantifying heterogeneity in a metaanalysis. Stat. Med. 21, 1539–1558. doi:10.1002/sim.1186

Huang, C., Liao, H., Ren, L., Zhou, Y., and Li, Z. (2013). Observation of curative effect and adverse reactions of elemene combined with chemotherapy in the treatment of malignant tumor. J. Pract. Oncol. 28, 417–418. doi:10.13267/j.cnki.syzlzz.2013.04.012

Jewer, M., Lee, L., Leibovitch, M., Zhang, G., Liu, J., Findlay, S. D., et al. (2020). Translational control of breast cancer plasticity. *Nat. Commun.* 11, 2498. doi:10.1038/ s41467-020-16352-z

Keklikoglou, I., Cianciaruso, C., Güç, E., Squadrito, M. L., Spring, L. M., Tazzyman, S., et al. (2019). Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. *Nat. Cell Biol.* 21, 190–202. doi:10.1038/s41556-018-0256-3

Kong, N., Zhang, R., Wu, G., Sui, X., Wang, J., Kim, N. Y., et al. (2022). Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer. *Proc. Natl. Acad. Sci. U. S. A.* 119, e2112696119. doi:10.1073/pnas. 2112696119

Lei, J., Liu, Y., Zeng, J., and Lu, Y. (2018). Influence of Elemene Injection plus chemotherapy on the immune function and curative effect in patients with advanced

non-small cell lung cancer. Chin. Clin. Oncol. 23, 160-163. doi:10.3969/j.issn.1009-0460.2018.02.013

Liu, J. (2000). Efficacy of elemene emulsion combined with MVP regimen in the treatment of advanced lung cancer. *Henan J. Oncol.* 13, 434–435.

Liu, S., Li, Q., Li, G., Zhang, Q., Zhuo, L., Han, X., et al. (2020). The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by  $\beta$ -elemene. *Cell Death Dis.* 11, 969. doi:10.1038/s41419-020-03148-8

Liu, S., Zhou, L., Zhao, Y., and Yuan, Y. (2015).  $\beta$ -elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway. *Oncol. Rep.* 34, 943–951. doi:10.3892/or.2015.4050

Liu, X., Li, Y., Bai, N., Yu, C., Xiao, Y., Li, C., et al. (2022). Updated evidence of dengzhan shengmai capsule against ischemic stroke: A systematic review and metaanalysis. *J. Ethnopharmacol.* 283, 114675. doi:10.1016/j.jep.2021.114675

Liu, X., Liu, J., and Dong, Y. (2021). Effects of elemene on the immune function of patients with colorectal cancer after adjuvant chemotherapy. *Hebei Med. J.* 43, 3092–3095. doi:10.3969/j.issn.1002-7386.2021.20.011

Lu, L., and Zhao, T. (2011). Observation on the therapeutic effect of thanscateter hepatic arterial chemoembolization infusion combined with elemene emulsion for metastatic liver carcinomas. *Chin. Arch. Tradit. Chin. Med.* 29, 253–255. doi:10.13193/j. archtcm.2011.02.31.lulq.082

Ma, L. T., Bai, Y., Li, J., Qiao, Y., Liu, Y., and Zheng, J. (2021). Elemene emulsion injection administration reduces neuropathic pain by inhibiting astrocytic NDRG2 expression within spinal dorsal horn. *Chin. J. Integr. Med.* 27, 912–918. doi:10.1007/s11655-021-3438-3

Middleton, J. D., Sivakumar, S., and Hai, T. (2021). Chemotherapy-induced changes in the lung microenvironment: The role of MMP-2 in facilitating intravascular arrest of breast cancer cells. *Int. J. Mol. Sci.* 22, 10280. doi:10.3390/ijms221910280

Mu, L., Wang, T., Chen, Y., Tang, X., Yuan, Y., and Zhao, Y. (2016).  $\beta$ -Elemene enhances the efficacy of geftinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway. *Int. J. Oncol.* 49, 1427–1436. doi:10.3892/ ijo.2016.3626

Pan, Y., Wang, W., Huang, S., Ni, W., Wei, Z., Cao, Y., et al. (2019). Beta-elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation. *J. Cell Mol. Med.* 23, 6846–6858. doi:10.1111/jcmm.14568

Qian, Y., Zhang, Y., Lu, X., and Ji, H. (2020). Efficacy and safety of elemene combined with SOX in the treatment of advanced metastatic gastric cancer. *J. Hainan Med. Univ.* 26, 117–121+125. doi:10.13210/j.cnki.jhmu.20200103.001

Qin, S., Qian, J., Wang, L., He, Z., and Ma, Y. (1998). The clinical study on the plan of elemene emulsion with CTV to treat lung carcinoma. *Cancer Res. Prey Treat.* 25, 58–60.

Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., et al. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. *BMJ* 350, g7647. doi:10.1136/bmj. g7647

Shi, Y., Wang, Q., and Zheng, K. (2019). Effect of elemene oral emulsion combined with chemotherapy in treatment of advanced esophageal cancer. *Chin. J. Mod. Med.* 29, 88–92. doi:10.3969/j.issn.1005-8982.2019.19.016

Siegel, R. L., Miller, K. D., Fuchs, H. E., and Jemal, A. (2021). Cancer statistics, 2021. *CA Cancer J. Clin.* 71, 7–33. doi:10.3322/caac.21654

Song, F. L., Song, F. P., Li, T., Li, J. H., Wu, X. L., and Kang, N. (2015). Elemene combined with NP chemotherapy in the treatment of advanced non-small-cell lung carcinoma. *Med. Recapitulate* 21, 1710–1712. doi:10.3969/j.issn.1006-2084.2015.09.068

Tao, L., Wang, S., Zhao, Y., Wang, A. Y., Zhang, L., Ruan, J. S., et al. (2016). Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis. *Chin. J. Integr. Med.* 22, 795–800. doi:10.1007/s11655-015-2405-x

Tao, Y., Liao, X., Ruan, J., Ji, H., Zhao, D., and Gu, X. (2021). Effect of elemene oral emulsion combined with SOX regimen on the level of TAP in peripheral blood in treatment of patients with advanced gastric cancer. *Chin. J. Integr. Tradit. West Med. Dig.* 29, 28–31. doi:10.3969/j.issn.1671-038X.2021.01.06

Vaitkiene, P., Pranckeviciene, A., Stakaitis, R., Steponaitis, G., Tamasauskas, A., and Bunevicius, A. (2019). Association of miR-34a expression with quality of life of glioblastoma patients: A prospective study. *Cancers (Basel)* 11, 300. doi:10.3390/cancers11030300

Wang, H., Wu, X., and Li, L. (2012). Clinical efficacy of Elemene injection combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer. *J. Mod. Oncol.* 20, 978–980. doi:10.3969/j.issn.1672-4992.2012.05.33

Wang, L., Wu, Q., Zhou, Y., and Pang, G. (2018). Clinical observation of elemene injection in the treatment of advanced gastric cancer. *Clin. Misdiag Misther* 31, 81–84. doi:10.3969/j.issn.1002-3429.2018.04.024

Wang, X., Liu, Z., Sui, X., Wu, Q., Wang, J., and Xu, C. (2019). Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: A meta-analysis following the prisma guidelines. *Phytomedicine* 59, 152787. doi:10.1016/j.phymed.2018.12.010

Wu, X., Yue, C., Cui, X., and Li, S. (2018). Clinical effect and prognosis analysis of elemene combined with chemotherapy in the treatment of patients with malignant pleural mesothelioma. *Pract. J. Cancer* 33, 1427–1429. doi:10.3969/j.issn.1001-5930.2018.09.011

Xu, J., Zheng, R., and Wang, Y. (2018). The Clinical efficacy and safety of elemene injection combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer. *Pract. J. Cancer* 33, 1878–1881. doi:10.3969/j.issn.1001-5930.2018.11.041

Xu, K., Song, Z., and Xie, T. (2017). Influence of elemene on advanced breast cancer patients and immune function. *Liaoning J. Tradit. Chin. Med.* 44, 1665–1667. doi:10. 13192/j.issn.1000-1719.2017.08.036

Yu, J., Chen, Y., and Xu, Y. (2020). Improvement effects of elemene injection in combination with FOLFOX4 regimen on quality of life in patients with medium and advanced gastric cancer. *Chin. J. Integr. Tradit. West Med. Dig.* 28, 12–14+19. doi:10. 3969/j.issn.1671-038X.2020.01.04

Zeng, D., Bi, Y., Ling, Y., and Yang, Q. (2011). Clinical research of elemene emulsion combined with FOLFOX 4 regimen for advanced gastric cancer. *Chin. Clin. Oncol.* 16, 917–919. doi:10.3969/j.issn.1009-0460.2011.10.013

Zhai, B., Zeng, Y., Zeng, Z., Zhang, N., Li, C., Zeng, Y., et al. (2018). Drug delivery systems for elemene, its main active ingredient  $\beta$ -elemene, and its derivatives in cancer therapy. *Int. J. Nanomedicine* 13, 6279–6296. doi:10.2147/IJN.S174527

Zhai, B., Zhang, N., Han, X., Li, Q., Zhang, M., Chen, X., et al. (2019). Molecular targets of  $\beta$ -elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review. *Biomed. Pharmacother.* 114, 108812. doi:10. 1016/j.biopha.2019.108812

Zhang, K., Erkan, E. P., Jamalzadeh, S., Dai, J., Andersson, N., Kaipio, K., et al. (2022a). Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. *Sci. Adv.* 8, eabm1831. doi:10.1126/sciadv.abm1831

Zhang, L., Xu, K., Zhang, X., Li, L., Chong, J., and Yu, N. (2022b). A meta-analysis and trial sequential analysis of high intensity focused ultrasound ablation combined with transhepatic arterial chemotherapy and embolization for hepatoma. *Front. Oncol.* 12, 1025177. doi:10.3389/fonc.2022.1025177

Zhang, L., Zhang, J., Wang, Y., and Tan, P. (2019). Efficacy of elemene injection assisted cisplatin in patients with non-small cell lung cancer and influence on the expression of mismatched repair proteins. *Hebei Med. J.* 25, 70–75. doi:10.3969/j.issn. 1006-6233.2019.01.018

Zhang, M. (1997). Clinical observation of elemene on chemosensitizing effect of lung cancer. *Anhui Med. J.* 18, 42.

Zhang, Y., Mu, X. D., Li, E. Z., Luo, Y., Song, N., Qu, X. J., et al. (2013a). The role of E3 ubiquitin ligase Cbl proteins in  $\beta$ -elemene reversing multi-drug resistance of human gastric adenocarcinoma cells. *Int. J. Mol. Sci.* 14, 10075–10089. doi:10.3390/ijms140510075

Zhang, Y., Zhang, C., and Meng, J. (2013b). Clinical analysis of elemene injection adjuvant VAD chemotherapy treatment multiple myeloma. *Chin. J. Exp. Tradit. Med. Form.* 19, 313–316. doi:10.11653/syfj2013230313

Zhao, C., Zhang, Y., Sun, Y., and Jia, Y. (2012). Clinical study of elemene injection combined with interventional chemotherapy in the treatment of primary liver cancer. *Chin J Diffic Compl Cas* 11, 882–883. doi:10.3969/j.issn.1671-6450.2012.11.031

Zhao, S., Zang, H., and Gu, X. (1999). Emulsion Elemene plus combination chemotherapy in treatment of refractory acute nonlymphocytic leukemia. *Chin. J. Clin. Oncol.* 26, 46–47. doi:10.3969/j.issn.1000-8179.1999.07.016

Zhao, X., Jin, H., Zhou, Y., and Pang, G. (2018). Efficacy of elemene injection combined with TP regimen in the treatment of advanced non-small cell lung cancer. *Chin. J. Hosp. Pharm.* 38, 165–168. doi:10.13286/j.cnki.chinhosppharmacyj.2018.02.12

Zhao, Y. F., Wang, C. R., Wu, Y. M., Ma, S. L., Ji, Y., and Lu, Y. J. (2011). P21 (waf1/ cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment. *Biomed. Pharmacother.* 65, 151–156. doi:10.1016/j.biopha.2011.02.009

Zheng, C., Cai, X., Wu, S., Liu, Z., Shi, Y., and Zhou, W. (2014). Enhancing effect of  $\beta$ elemene emulsion on chemotherapy with harringtonine, aclacinomycin, and Ara-c in treatment of refractory/relapsed acute myeloid leukemia. *Pak J. Med. Sci.* 30, 1270–1272. doi:10.12669/pjms.306.5207

Zheng, C., Wang, X., Zhang, W., and Xu, J. (1999). Emulsion elemene plus combination chemotherapy in treatment of acute nonlymphocytic leukemia. *Chin. J. Clin. Oncol.* 26, 237–238.

Zhong, M., and Hao, C. (2019). Therapeutic effect of elemene injection combined with trastuzumab and chemotherapy on patients HER2-positive advanced gastric cancer. *Chin. J. Integr. Tradit. West Med. Dig.* 27, 662–666. doi:10.3969/j.issn.1671-038X.2019.09.04

Zhou, J., He, L. L., Ding, X. F., Yuan, Q. Q., Zhang, J. X., Liu, S. C., et al. (2016). Combinatorial antitumor effect of rapamycin and  $\beta$ -elemene in follicular thyroid cancer cells. *Biomed. Res. Int.* 2016, 6723807. doi:10.1155/2016/6723807

Zhou, L. (2010). Efficacy analysis of elemene combined with paclitaxel liposome and cisplatin in the treatment of non-small cell lung cancer. *Chin. J. Clin. Oncol.* 37, 411–412. doi:10.3969/j.issn.1000-8179.2010.07.015

Zhou, L., Liu, F., Zhang, H., Jiang, N., Zhao, Y., and Cao, Y. (2009). Clinical observation of elemene injection combined paclitaxel chemotherapy on advanced stage nonsmall-cell lung cancer. *Pharmacol. Clin. Chin. Mater Med.* 25, 113–115. doi:10.13412/j.cnki.zyyl.2009.02.057

Zhu, J., Jiang, S., Jiang, X., Luo, K., Huang, X., and Hua, F. (2022). Association of blood lipocalin-2 levels with gestational diabetes mellitus: A systematic review and metaanalysis. *Horm. Metab. Res.* 54, 677–685. doi:10.1055/a-1909-1922